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Abstract
Previous work on two-treatment comparisons has shown that the use of optimal
response-adaptive randomisation with group sequential analysis can allocate more
patients to the better-performing treatment while preserving the overall type I
error rate. The sequence of test statistics for this adaptive design asymptotically
satisfies the canonical joint distribution. The overall type I error rate can be con-
trolled by utilising the error-spending approach. However, previous work focused
on immediate responses. The application of the adaptive design to censored sur-
vival responses is investigated and different optimal response-adaptive randomised
procedures compared. For a maximum duration trial, the information level at the
final look is usually unpredictable. An approximate information time is defined.
Several treatments are often compared in a clinical trial nowadays. The adap-
tive design generalised to multi-arm clinical trials is studied. First, a global test
is considered. The joint distribution of the sequence of test statistics no longer
has the canonical distribution. However, the joint distribution can be derived,
since the test statistic is a quadratic form of independent normal variables. Exist-
ing critical boundaries are based on normal responses and known variances with
equal allocation and equal increments in information. Our results show that these
boundaries can be used approximately for designs with other types of responses,
unequal variances or unbalanced allocation.
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Abstract
If the global null hypothesis is rejected, then pairwise comparisons are conducted
at the current and subsequent looks to investigate which treatment effects differ.
This is an analogue of Fisher’s least significant difference method that can control
the family-wise error rate. The adaptive design can target any optimal allocation
to achieve some optimality criterion, and allows dropping of inferior treatments at
interim looks, which can be unequally spaced in information time. Optimal allo-
cation proportions after dropping arms are described. The power is not adversely
affected by unbalanced allocation.
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The use of a sequential test in clinical trials can require fewer patients than a
fixed-sample design to achieve the same error probabilities (Jennison and Turn-
bull, 2000). It allows early stopping when either a significant treatment effect or
futility is detected, and hence saves time and resources. Also, the use of sequential
monitoring can ensure that the protocol is followed well and that the assumptions
are not violated. Fully sequential designs that continuously evaluate treatment ef-
fects after each response observed are often unrealistic. Periodic group sequential
designs, in which a number of interim analyses are conducted after groups of ob-
servations, are more practical. With these advantages, group sequential analysis
has become standard practice for phase III clinical trials (Jennison and Turnbull,
2000). In addition, it is reported in recent studies that group sequential analysis
is the most popular adaptive design used in medical studies (Dimairo et al., 2015;
Hatfield et al., 2016).
The probability of falsely rejecting the null hypothesis increases when the num-
ber of group sequential tests is increased. Typically, the sample size and critical
boundaries are determined to attain the pre-specified error probabilities. There
are different discrete stopping boundaries, which require a pre-specified number of
interim analyses and equally spaced information levels between looks. The bound-
aries of Pocock (1977) spend the same proportion of the type I error rate at each
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look, whereas these of O’Brien and Fleming (1979) spend little of the type I error
rate at early looks, and hence the critical value for the final look is close to that
of a fixed-sample design.
However, it is often impracticable to pre-specify the number of interim analy-
ses and they are sometimes conducted at unequally spaced information levels. For
instance, when patient recruitment is slow, investigators may wish to postpone
the time of conducting an analysis. It may even end up that the sample size at
the planned end of the study is too small. Then the trial continues to recruit more
patients and additional group sequential analyses are needed. To this end, Lan
and DeMets (1983) proposed continuous critical boundaries derived from a user-
selected error-spending function. An error-spending function spends the error rate
with the information time, which is the ratio of the current information level to
the expected information level at the final look. This approach allows the interim
analyses to take place at any continuous information time, while preserving the
nominal type I error probability.
In group sequential monitoring, trials can be terminated early. Hence, patients
can be prevented from being exposed to inferior or unsafe treatments. In addi-
tion, response-adaptive randomisation, which skews the allocation proportion of
the sample sizes towards the more promising treatments based on the responses
observed, can further reduce the numbers of patients allocated to the inferior
treatments compared to complete randomisation (Hu and Rosenberger, 2006).
Nevertheless, a lower inferior treatment number usually leads to an increase in
the expected total sample size (Jennison and Turnbull, 2001). Moreover, the use
of response-adaptive randomisation may increase the variability in the allocation,
which could adversely affect the power to detect the differences in treatment ef-
fects (Hu and Rosenberger, 2003). Therefore, response-adaptive randomisation
methods usually seek to balance the competing goals of individual and collective
– 2 –
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ethics, by allocating more patients to the better-performing treatment, minimising
the total sample size and maximising the power.
There are different response-adaptive randomisation methods. One family is
the urn-model type designs for dichotomised responses (Rosenberger and Lachin,
2002), including the randomised play-the-winner (RPW) design (Wei and Durham,
1978) and the drop-the-loser rule (Ivanova, 2003). The idea of this family of designs
is that treatment assignment is determined by drawing a ball from an urn, and
the composition of the balls is updated after each response. For example, for the
RPW design, if a success is observed, an additional ball of the same type is added
to the urn. Otherwise, an additional ball of the opposite type is added. Hence,
the probability of drawing the type of ball corresponding to the better treatment
increases. Another type of response-adaptive sampling rule is characterised by a
loss function, which is a weighted sum of the sample sizes on each treatment, with
a lower cost assigned to the better treatment (Jennison and Turnbull, 2000, 2001).
Although both types of response-adaptive randomisation method can reduce the
expected number of failures, the first type are not derived based on an optimality
criterion.
For optimal response-adaptive randomised designs (Atkinson and Biswas, 2014;
Antognini and Giovagnoli, 2015), a specific criterion is optimised based on the
assumed response model to obtain an optimal allocation. For instance, a stan-
dard optimality criterion for binary responses is to minimise the expected number
of failures. Different optimal response-adaptive randomisation procedures have
been proposed, including the popular doubly-adaptive biased coin design (DBCD)
(Eisele and Woodroofe, 1995) and the efficient randomised-adaptive design (ER-
ADE) (Hu et al., 2009). An advantage of these designs is that they can target any
specified optimal allocation based on some optimality criterion. Throughout the
thesis, we will focus on optimal response-adaptive randomisation.
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Jennison and Turnbull (2001) derived theory to support that the combined ap-
proach of group sequential analysis with response-adaptive randomisation still
maintains the overall error rates for two-armed normal trials with known vari-
ances. The authors proved that the joint distribution of the test statistics has
a standard form similar to that for a group-sequential non-adaptive design, but
with the additional feature that the information level can depend on previous test
statistics. Their simulation results also show that the nominal error rates are
attained for the combined approach. In addition, a reduction in the inferior treat-
ment number can be achieved at a cost of a slight increase in the expected total
sample size. In addition, Morgan (2003a) proposed two inferential methods for
the treatment mean difference following such a group-sequential response-adaptive
design. One considered approximate confidence intervals using a pivotal method,
and the other constructed a bias-adjusted maximum likelihood estimator.
Morgan (2003b) investigated the combined approach for normal responses with
unknown variances. As inaccurate estimates of the variances of the responses can
influence the power considerably, she suggested using sample size re-estimation
based on the new estimates of the variances updated by the observed responses.
For two-armed binary trials, Morgan and Coad (2007) compared several adap-
tive allocation rules in a group sequential setting, including two urn-model type
designs, the DBCD and sequential maximum likelihood estimation (SMLE) rule,
which minimise the expected number of failures and is a special case of the DBCD.
Among the designs they investigated, the drop-the-loser rule (Ivanova, 2003) is
found to be the most efficient method for achieving the competing objectives of
reducing the expected number of failures and the expected total sample size.
Zhu and Hu (2010) studied the combined approach of group sequential analysis
with optimal response-adaptive randomisation for two-armed clinical trials with
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normal and binary responses. By considering monitoring the response-adaptive
design at a continuous information time, Zhu and Hu (2010) proved that the
sequence of test statistics converged to a Brownian motion in distribution and
asymptotically satisfied the canonical joint distribution proposed by Jennison and
Turnbull (2000) for standard group sequential designs. Continuous boundaries
obtained by the error-spending approach (Lan and DeMets, 1983) can be used
to control the nominal type I error rate. The simulation results in Zhu and Hu
(2010) reveal that the use of the combined approach can preserve the advantages
of both group sequential analysis and optimal response-adaptive randomisation.
However, the authors focused on the popular DBCD for two-armed trials with
immediate responses. The application of the combined approach to two-armed
censored survival trials and to multi-armed experiments has not yet been studied.
This will be investigated in the thesis, with various designs compared.
1.2. Literature review
1.2.1. Two-armed survival responses
Survival or time-to-event responses usually have a heavy upper tail. Therefore, the
assumption of normality is not appropriate. One of the common statistical models
for survival responses is the proportional hazards model (Cox and Oakes, 1984),
which assumes that a unit increase in an explanatory variable will multiplicatively
affect the hazard rate. The main focus is the hazard ratio, which can be estimated
regardless of the unknown hazard function. However, the strong assumption of
proportional hazards, which implies that the hazard rates for different treatments
can never cross, may be unrealistic in practice.
Another commonly-seen method is the non-parametric logrank test. Group se-
quential monitoring of logrank tests has been discussed (Jennison and Turnbull,
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2000). For survival responses, the information levels usually cannot be attained
accurately, since they depend on the realised pattern of events and censoring. How-
ever, for the group sequential logrank test, the information level can be approxi-
mated by the observed number of events divided by four, under the assumption
that the numbers at risk are similar in each treatment arm. Yet, equal allocation
across treatment groups was considered. The sample size for each arm is chosen
to attain the information level.
For optimal response-adaptive randomisation, the target allocation proportions are
usually unbalanced and depend on the unknown parameters. Zhang and Rosen-
berger (2007) derived optimal allocations for two-armed censored survival trials
with exponential and Weibull distributions. The optimal allocations are derived
based on different optimality criteria, such as minimising the total sample size
or the total expected hazard. Then the DBCD is applied to target the speci-
fied optimal allocation. The authors considered the priority queue data structure
(Rosenberger and Seshaiyer, 1997), which assumes uniformly distributed staggered
entry and right censoring. It is shown in theory that a delay in response has little
effect on the asymptotic variance of the DBCD procedure. In addition, simulation
results show that the use of the DBCD results in more patients being allocated
to the more promising treatment without a loss of power. Nevertheless, a fixed-
sample design was used.
1.2.2. Multi-armed clinical trials
Several treatments are often compared in a clinical trial nowadays (Follmann et al.,
1994). For multiple comparisons, one needs to ensure that the family-wise error
rate is preserved, since the more pairwise comparisons that are made, the higher
the probability that a null hypothesis will be rejected. For all pairwise compar-
isons, p = J(J − 1)/2 tests are conducted, where J is the number of treatments.
– 6 –
1. Introduction
For comparisons with a common control, there are p = J − 1 tests. To this end,
many approaches based on fixed-sample designs have been proposed. One simple
approach is the Bonferroni adjustment, which uses α/p as the nominal type I error
rate for each pairwise test. In group sequential monitoring, pairwise comparisons
are repeatedly carried out at each look. One also needs to ensure that the overall
type I error rate is controlled. The Bonferroni approach can be extended to group
sequential designs by replacing α with αk, the type I error rate spent by interim
analysis k.
In addition, Follmann et al. (1994) obtained exact critical boundaries for group se-
quential pairwise tests for tests on means and survival distributions using logrank
tests, under the assumption of equal variances or censoring distributions for each
arm. The authors pointed out that the difference between the critical values for the
exact methods and those using the Bonferroni adjustment is very modest. More-
over, the Bonferroni approach is more flexible, which allows unequal allocation
across treatment groups, and, if desired, different shapes of critical boundaries for
different pairwise comparisons. Both the Bonferroni and exact methods strongly
control the overall type I error rate. However, they can be too conservative at the
price of losing power.
Another approach to group sequential monitoring of multi-armed clinical trials
is to use a global test. Jennison and Turnbull (1991, 2000) derived critical bound-
aries analogous to Pocock’s and the O’Brien and Fleming boundaries. These are
derived based on multi-armed normal trials with equal variances and equal treat-
ment allocation. For the unequal variances case, Proschan et al. (1994) suggested
obtaining the critical boundaries by simulation. Alternatively, by the significance
level approach, the critical boundaries derived under the assumption of equal vari-
ances can be used as an approximation (Jennison and Turnbull, 2000). Neverthe-
less, these studies do not consider the incorporation of response-adaptive sampling
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rules in the group sequential analysis. The optimal response-adaptive randomisa-
tion procedures have been generalised to multi-armed trials using a fixed-sample
design, including the DBCD (Hu and Zhang, 2004) and the ERADE (Zhang,
2016). Whether the combined approach for multi-armed trials still preserves the
error rates while targeting some optimality criterion is of concern in this thesis.
However, the global test focuses on a test of homogeneity. The critical bound-
aries used are based on the joint distribution of the test statistics assuming that
sampling for all treatments continues to the end of the trial. Dropping of inferior
treatments violates this underlying assumption.
1.2.3. Multi-armed clinical trials with dropping of arms
In group sequential monitoring, when an inferior treatment is identified at an in-
terim look, it is unethical to continue assigning patients to that arm. Fisher’s
least significance difference (LSD) method is considered to be one of the most
powerful multiple comparison methods (Christensen, 2002). A group sequential
Fisher’s LSD method was proposed by Proschan et al. (1994). First, a global test
statistic is monitored sequentially to test for the homogeneity of treatment effects.
If the global null hypothesis is rejected, unadjusted pairwise comparisons are con-
ducted at this and subsequent looks if the trial proceeds. Inferior treatments can
be dropped after the pairwise comparisons. However, the study of Proschan et al.
(1994) only considered the cases of equal allocation and fixed unequal allocation
determined prior to the commencement of the experiment. Implementation of
optimal response-adaptive randomisation in a fixed-sample Fisher’s LSD design
has been studied, including Tymofyeyev et al. (2007) for binary responses and
Sverdlov et al. (2011) for censored survival responses. These studies considered
the popular DBCD. One objective of the thesis is to extend this work to group




Other studies considered using multi-armed multi-stage (MAMS) designs to mon-
itor multi-armed clinical trials (Magirr et al., 2012; Wason et al., 2016). MAMS
designs simultaneously evaluate several regimens against a common control. With
efficacy and futility boundaries, the designs allow dropping of inferior treatments
at interim analyses. MAMS designs are shown to strongly control the type I er-
ror rate, which means that the probability of falsely rejecting one or more null
hypotheses is less than or equal to α (Bratton et al., 2016). However, response-
adaptive randomisation has not been incorporated in MAMS designs. The number
of patients needed per arm per stage and the critical boundaries are obtained by
numerical computation. In this thesis, Fisher’s LSD method generalised to group-
sequential response-adaptive designs will be the focus.
1.3. Structure of chapters
In Chapter 2, the study of Zhu and Hu (2010) that combines group sequential
analysis with the DBCD for two-armed trials with immediate responses is de-
scribed and compared to that using the ERADE by simulation in Section 2.2.
An extension of the combined approach to censored survival responses is provided
in Section 2.3. The issue of right censoring in group sequential analysis is taken
into account in the model. For instance, if a subject has not responded at the
time when an interim test is conducted, the true survival time is greater than the
observed survival time. Right censoring caused by lost to follow-up due to death
from an unrelated cause or emigration is also considered. For maximum duration
trials, an approximation to the information time for censored survival responses is
obtained, which depends on the assumed models for patient entry, survival time
and censoring. The error-spending approach can be applied to control the overall




In Chapters 3 and 4, extensions of the combined approach to several treatment
comparisons are investigated. Chapter 3 considers a global test. The global test
statistics for different types of responses are described in Section 3.1. Critical
boundaries derived by Jennison and Turnbull (1991, 2000) are applied as an ap-
proximation for the designs. For optimal response-adaptive randomisation, the
DBCD and the ERADE generalised to multi-treatment trials are given in Section
3.2. Two optimal allocations for multi-armed trials are considered. One ensures
the most efficient treatment effect estimates and the other maximises the power
of tests of homogeneity while fixing the total sample size. Properties of the group-
sequential response-adaptive design for multi-treatment trials are investigated by
simulation in Section 3.3, where both equal and unequal increments in informa-
tion time are considered. In addition, results for a fixed-sample design with one
analysis conducted at the end of the trial are provided alongside for comparison.
Chapter 4 explores an analogue of Fisher’s LSD method generalised to group-
sequential response-adaptive designs. The global and pairwise tests are discussed
in Section 4.1. Any treatment that is inferior to the control can be discarded after
the pairwise comparisons. The information time for trials that allow dropping
arms is described in Section 4.2. Optimal allocation proportions after dropping
treatments are described in Section 4.3. Properties of the analogue of Fisher’s
LSD method generalised to group-sequential optimal response-adaptive designs
are investigated by simulation in Section 4.4. In addition, simulation results of
redesigning a four-armed clinical trial are summarised.
Conclusions are drawn in Chapter 5, together with a discussion of the limitations
and possible extensions to the research. Programs for the simulation studies are
written in the statistical software R. In addition, for censored survival responses,
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the optimal allocations depend on the probability of an event, which is calculated
in Appendix A based on the assumed models for patient arrival, survival and cen-
soring time described in Section 2.3.2. For the global tests on means, Appendix







2.1.1. Form of test
Information time
Suppose that N is the planned maximum number of patients for a trial with K
group sequential analyses. For immediate responses including normal and binary
endpoints, the information level is proportional to the number of subjects recruited
(Jennison and Turnbull, 2000). As the trial proceeds, we obtain more responses











, k = 1, ..., K, (2.1)
where Ik denotes the information level at group sequential test k, mj,k is the cu-
mulative number of patients on treatment j, j = 1, 2, at look k, mj,K = Mj, and
nk =
∑2
j=1mj,k is the cumulative total sample size at look k, nK = N .
Interim analyses can be conducted at any continuous information time tk ∈ (0, 1].
For example, suppose that we wish to conduct the first interim test when about
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one quarter of the maximum sample size has been recruited. Then the information
time at the first look is set as t1 = 0.25 and about n1 = dt1Ne patients are needed.
Here, dxe is the smallest integer greater than or equal to x. If the trial continues
to the end of the study without early termination, then tK = 1 and the maximum
number of patients N is reached.
Test statistics
Normal responses
Assume that the response for patient i, i = 1, ....,mj,k, on treatment j, j = 1, 2,






Suppose that the parameter of interest is the difference in treatment effects, φ =
µ1 − µ2. We wish to test the null hypothesis H0 : φ = 0 versus the alternative








∼ N(0, 1) (2.2)







is the sample variance for arm j at look k.
For optimal response-adaptive randomisation, the cumulative number of patients
on treatment j at look k, mj,k, is random. However, the allocation proportions
converge almost surely to the pre-specified optimal allocation proportions derived
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based on some optimality criterion (Hu and Rosenberger, 2003). More precisely,
let ρj be the target optimal allocation proportion for treatment j. Previous work
has shown that Mj/N converges to ρj almost surely for a fixed-sample design.
Hence, Mj can be approximated by ρjN .
For group-sequential optimal response-adaptive designs, where repeated analyses
are conducted using the cumulative responses, we have mj,k = ρjnk approximately.
Since ρj is usually a function of the unknown parameters, let ρ̂ = (ρ̂1, ρ̂2) be the










Some commonly-used optimal allocations will be introduced in Section 2.1.2. Here,
the required cumulative sample size at look k, nk, to achieve the specified infor-
mation level can be obtained from (2.1).
In practice, the actual observed number of patients is used for mj,k in (2.2). Un-
equal increments in the observed information levels may occur. Critical boundaries
that control the overall type I error rate can be obtained by using the error-
spending approach (Lan and DeMets, 1983), which spends the type I error rate
as a function of the information time. More details will be given later.
Binary responses
For binary endpoints, the responses are dichotomous rather than continuous. For
instance, the responses may indicate whether or not a patient responds to a given
treatment. The response for patient i on treatment j, Yi,j, is Bin(1, pj). Here, the
parameter pj is the probability of success on treatment j, and qj = 1 − pj is the
failure rate. For arm j at look k, we have the estimates
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and q̂j,k = 1− p̂j,k.
Consider testing H0 : φ = 0 versus Ha : φ 6= 0, where φ = p1 − p2, to compare the
















Under H0, the marginal distribution of Zk in (2.3) is asymptotically standard nor-
mal for large sample sizes using the Central Limit Theorem.
Joint distribution of the sequence of test statistics
A common form of the joint distribution of {Z1, ..., ZK} has been derived by Jenni-
son and Turnbull (2000), which is called the canonical joint distribution and stated
as follows. Given information levels {I1, ..., IK}, (i) {Z1, ..., ZK} is multivariate
normal, (ii) E(Zk) = φ
√
Ik and (iii) cov(Zk1 , Zk2) =
√
Ik1/Ik2 , 1 ≤ k1 ≤ k2 ≤ K.
Let φ̂k be the parameter estimate at look k, so that Ik = {var(φ̂k)}−1. This form
applies exactly for normal responses with known variances and approximately for
other types of endpoints, including right-censored survival responses.
For a two-sample normal test using an adaptive sampling rule, which seeks to
balance the competing goals of lowering the number of patients allocated to the
inferior treatment and reducing the expected total sample size, Jennison and Turn-
bull (2001) showed that the standard form of the canonical joint distribution still
holds, provided that the group sizes are computed to satisfy the given information
levels.
Consider two-armed trials using optimal response-adaptive randomisation, which
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can target any specified optimal allocation, and allow an interim analysis to
be taken at a continuous information time. Zhu and Hu (2010) proved that
the sequence of test statistics converges to Brownian motion in distribution and
that the joint distribution asymptotically satisfies the canonical joint distribution.
More specifically, they showed that (i) {Z1, ..., ZK} is multivariate normal, (ii)
E(Zk) = µ
√
Ntk and (iii) cov(Zk1 , Zk2) =
√
tk1/tk2 , 0 ≤ tk1 ≤ tk2 ≤ 1, where,




2/ρ2, N is the maximum sample
size and tk is the information time at look k. As the canonical joint distribution
still holds asymptotically for group-sequential response-adaptive designs, the re-
quired error probabilities can also be achieved using the same approach as for a
non-adaptive randomised design.
The error-spending approach
The error-spending approach can be used to maintain the error rate at the spec-
ified value for any observed information sequence {I1, ..., IK}, provided that Ik
is conditionally independent of previous parameter estimates {φ̂1, ..., φ̂k−1} given
{I1, ..., Ik−1}. Otherwise, the standard form of the canonical joint distribution
will fail to hold. There are two types of error-spending functions, the α-spending
function and the β-spending function which are used to control the type I and
type II error rates, respectively. Throughout this thesis, we consider the former
error-spending function.
An α-spending function, α(tk), represents how much of the cumulative type I error
rate is to be spent at information time tk = Ik/IK . It is a continuous and mono-
tonically non-decreasing function with α(0) = 0 and α(1) = α. Proschan et al.
(2006) discussed three such functions. One approximates the O’Brien and Fleming
boundaries (O’Brien and Fleming, 1979), one approximates Pocock’s boundaries
(Pocock, 1977) and the third one is the linear α-spending function. We have
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αO−F (tk) = 2{1− Φ(zα/2/
√
tk)},
αP (tk) = α log{1 + (e− 1)tk},
αL(tk) = αtk,
(2.4)
where zα/2 = Φ
−1(1− α/2) and Φ denotes the standard normal distribution func-
tion.
The O’Brien and Fleming boundaries spend little type I error probability dur-
ing the early stages of a trial, and, if the last look is reached, the type I error rate
will be close to that of a fixed-sample design. In contrast, Pocock’s boundaries are
more likely to reject H0 earlier, and hence have a large critical value at the final
stage to attain the overall type I error rate. The linear boundaries are, in general,
between the two. The critical boundaries to be used need to be pre-specified in
the study protocol.
Based on the joint distribution of the sequence of test statistics, the critical bound-
aries {c1, ..., cK} can be calculated recursively using the equation
Pφ=0(|Z1| < c1, ..., |Zk−1| < ck−1, |Zk| ≥ ck) = α(tk)− α(tk−1).
For k = 1, the type I error probability to be spent is Pφ=0(|Z1| ≥ c1) = α(t1). The
critical boundary c1 can be easily obtained by inverting the standard normal dis-
tribution function. If the trial progresses, the probability of crossing the stopping
boundary at the second look is Pφ=0(|Z1| < c1, |Z2| ≥ c2) = α(t2) − α(t1), where
Z1 and Z2 follow a bivariate normal distribution. By integrating out Z1 from the
joint distribution of Z1 and Z2, c2 can be obtained. Similarly, the critical bound-
aries for the kth interim analysis, ck, k > 2, are computed through integration of
a multivariate normal distribution. This method does not require the number of
group sequential analyses, K, to be pre-specified.
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Stopping rules
Under group-sequential monitoring, a decision for early termination can be made
if there is sufficient evidence of a treatment effect or futility at interim analyses.
Otherwise, the trial proceeds to recruit more participants for more information
until it reaches the end of the trial. For a two-sided group-sequential monitoring
trial, the stopping rules are given below.
• For k = 1, ..., K − 1, stop the trial and reject the null hypothesis if |Zk| ≥ ck;
otherwise, continue to the next interim analysis.
• For k = K, reject H0 if |Zk| ≥ ck, and accept H0 otherwise.
2.1.2. Optimal response-adaptive randomisation
Optimal allocations
Optimal response-adaptive randomised designs aim to target the pre-specified op-
timal allocation derived based on some optimality criterion. Some common op-
timal allocations for testing treatment differences with immediate responses are
introduced below. These optimal allocations were derived using a fixed-sample de-
sign with one analysis conducted at the end of the trial, which is the case K = 1
in Section 2.1.1. The pre-specified optimal allocation should remain unchanged
regardless of the number of interim analyses.
Neyman allocation
Neyman allocation minimises the total sample size under a variance constraint.
For normal responses, we wish to minimise N = M1 + M2 with respect to M1,
subject to a fixed variance, σ21/M1+σ
2
2/(N−M1) = C, where C is a constant. The
solution obtained by Jennison and Turnbull (2000) using a loss function specialised
to the sum of the sample sizes on each treatment is
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and ρ2 = 1− ρ1. (2.5)








and ρ2 = 1− ρ1.
Neyman allocation has the merit of efficiency. It maximises the power of a two-
sample Z test for a fixed sample size. However, the solution is not always ethical.
The most efficient allocation may assign more patients to the inferior treatment.
Optimal allocation
For binary responses, an ethical optimal criterion is to minimise the total expected
number of failures, q1M1 + q2M2, under a variance constraint. Rosenberger et al.







and ρ2 = 1− ρ1. (2.6)
There are other optimal allocations derived based on different optimality criteria.
Here, we focus on these two widely-used optimal allocations, Neyman allocation
for normal responses and optimal allocation for binary responses.
The optimal allocations (2.5) and (2.6) depend on the unknown parameters. In
practice, the current parameter estimates are used, which are updated after each
response observed.
Optimal response-adaptive randomisation procedures
Response-adaptive randomisation assigns patients according to previous treatment
allocations and responses. Permuted-block randomisation can be used early on
to obtain initial parameter estimates. This method balances the sample sizes
across the treatment groups. For a two-treatment comparison, block sizes of
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{2, 4, 6, 8, ...} can be chosen. The sample sizes for the treatment groups are equal
within each block. For three-treatment comparisons, block sizes of {3, 6, 9, ...} can
be used. A more unpredictable allocation can be achieved by randomly select-
ing the block size. After obtaining initial parameter estimates, the two optimal
response-adaptive randomisation procedures below can be implemented.
Doubly-adaptive biased coin design (DBCD)
Suppose that m
(i)
j is the cumulative sample size on treatment j after i patients,
i = 1, ..., N . Let m
(i)
j /i and ρ̂
(i)
j be the current and optimal allocation proportions
for treatment j, j = 1, 2, evaluated based on the responses available. Eisele and
Woodroofe (1995) proposed a response-adaptive allocation probability, which is a
function of the current and optimal allocation proportions. The probability that



































}γ , if 0 < m(i)j /i < 1,
1−m(i)1 /i, if m
(i)
1 /i = 0, 1,
(2.7)
where 0 ≤ γ ≤ ∞ is a constant that determines the degree of randomness of the
allocation procedure. The procedure is the most random when γ = 0. In this
case, g1 = ρ̂
(i)
1 if 0 < m
(i)
j /i < 1, which corresponds to the sequential maximum
likelihood estimation procedure (Melfi and Page, 1998). The randomisation pro-
cedure is the most deterministic when γ approaches infinity. The design is then
the same as Thompson’s (1933) procedure, where g1 = 1 if m
(i)
1 /i < ρ̂
(i)
1 and g1 = 0
if m
(i)
1 /i ≥ ρ̂
(i)
1 . Many studies use γ = 2, which can achieve a high power while
allowing a reasonable degree of randomness.
Efficient randomised-adaptive design (ERADE)
Similar to the DBCD function, the allocation probability function for the ERADE
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depends on the current allocation proportion m
(i)
j /i and the estimated target allo-
cation proportion ρ̂
(i)
j , j = 1, 2. However, the ERADE function (Hu et al., 2009) is








1 , if m
(i)





1 , if m
(i)
1 /i = ρ̂
(i)
1 ,
1− γ′{1− ρ̂(i)1 }, if m
(i)




where 0 ≤ γ′ < 1 is a constant that controls the degree of randomisation. The ER-
ADE allocation procedure becomes more deterministic when γ
′
approaches zero.
A value of γ
′
between 0.4 and 0.7 is recommended (Hu et al., 2009).
The allocation probability for treatment 1, g1, using (2.7) or (2.8) is updated
sequentially after each response observed.
Asymptotic properties of optimal response-adaptive randomisation
Response-adaptive randomisation procedures are often compared in terms of op-
timality, variability and power. Previous work has shown that the limiting alloca-
tion proportions using optimal response-adaptive randomisation converge to the
target optimal allocation proportions almost surely (Hu and Rosenberger, 2003;
Zhang and Rosenberger, 2006). Optimality can be achieved by both the DBCD
and the ERADE with reasonably small variability in the allocation proportions.
In particular, the ERADE generally has a lower variability than the DBCD. Hu
et al. (2006) derived an asymptotic Cramér-Rao lower bound for the variance of
the allocation proportions. The DBCD has been shown to attain the lower bound
only when γ → ∞ (Zhang and Rosenberger, 2006). However, the ERADE has
been proved to always attain the lower bound (Hu et al., 2009).
Some previous work found that the use of optimal response-adaptive randomisa-
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tion increases the variance of the allocation proportions, which results in an adverse
effect on the power of tests (Melfi and Page, 1998; Hu and Rosenberger, 2003).
However, the results obtained by Zhu and Hu (2010) and Tymofyeyev et al. (2007)
show an increase in power. It is argued that the use of optimal response-adaptive
randomisation can lower the expected number of treatment failures without a loss
of power, or even lead to a higher power compared to complete randomisation.
In terms of the convergence rate, Zhang (2016) indicated that the ERADE may
not converge as fast as the DBCD in some situations. This may be because the
ERADE function is discontinuous for two-armed clinical trials, which can be less
stable as the allocation probabilities jump from one value to another.
2.2. Simulation studies for immediate responses
In this section, the simulation setting is similar to that of Zhu and Hu (2010).
However, more randomisation procedures are compared and different information
sequences considered.
2.2.1. Normal responses
Suppose that the maximum number of patients is N = 500. Permuted-block
randomisation is used for the first 10% of the maximum sample size to obtain
initial parameter estimates. Then the optimal response-adaptive randomisation
procedures, the DBCD and the ERADE, are applied using γ = 2 and γ
′
= 0.5,
respectively. Neyman allocation is used as the target optimal allocation. For
comparison with a non-adaptive randomised design, the results for complete ran-
domisation (CR) are included.
For group sequential analysis, there are K = 3 sequential tests planned at the
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unequally spaced information times (0.2, 0.5, 1) and (0.5, 0.8, 1). The former con-
ducts early interim looks, whereas the latter has interim analyses after reaching
half of the maximum information level. The overall type I error rate α = 0.05 is
set, and the O’Brien and Fleming critical boundaries derived by the error-spending
approach are used. The critical boundaries for the tests taken at the two infor-
mation sequences are (4.877, 2.963, 1.969) and (2.963, 2.266, 2.028), respectively.
Results of fixed-sample designs based on N patients are provided alongside for
comparison, which are a special case of the group sequential design with K = 1
and tK = 1. The critical value in this case is 1.960.
The designs are compared in terms of the error probabilities, the expected num-
ber of patients (ENP), the average allocation proportion for treatment 1 and the
corresponding variability. Rather than being adjusted to get a particular infor-
mation, the maximum number of patients N is fixed for all of the designs. The
results are based on 5,000 replicates.
Table 2.1.: Simulated type I error rate for two-armed normal trials with Neyman
allocation in group sequential and fixed-sample designs, µ1 = µ2 =
1, σ1 = 1, σ2 = 2, N = 500.
(t1, t2, t3)=(0.2, 0.5, 1)
Procedure α̃ ENP (s.d.) ρ̃1 (s.d.)
CR 0.048 499.0 (15.8) 0.500 (0.021)
DBCD 0.046 499.5 (11.2) 0.334 (0.019)
ERADE 0.040 499.4 (12.2) 0.334 (0.015)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure α̃ ENP (s.d.) ρ̃1 (s.d.)
CR 0.053 497.2 (19.6) 0.500 (0.021)
DBCD 0.057 496.6 (21.8) 0.334 (0.019)
ERADE 0.044 497.5 (18.9) 0.334 (0.015)
Fixed-sample design
Procedure α̃ ENP (s.d.) ρ̃1 (s.d.)
CR 0.048 500 (0) 0.501 (0.021)
DBCD 0.048 500 (0) 0.334 (0.019)
ERADE 0.051 500 (0) 0.334 (0.015)
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As can be seen from Table 2.1, all of the designs can well attain the pre-specified
value of the type I error rate, 0.05, with usually a discrepancy of less than three
standard errors. More specifically, α̃ lies within (0.041,0.059), except for the ER-
ADE when (t1, t2, t3)=(0.2, 0.5, 1), where α̃ just falls outside of this range. Under
the null hypothesis, the ENP is similar for all of the designs, since the chance of
early termination is small. For the optimal response-adaptive randomised designs,
the target Neyman allocation proportion for treatment 1 is ρ1 = 0.333 from (2.5).
Both the DBCD and the ERADE target ρ1 well, with the ERADE having a lower
standard deviation for the allocation proportion.
Table 2.2.: Simulated power for two-armed normal trials with Neyman allocation
in group sequential and fixed-sample designs, µ1 = 1.4, µ2 = 1, σ1 =
1, σ2 = 2, N = 500.
(t1, t2, t3)=(0.2, 0.5, 1)
Procedure Power ENP (s.d.) ρ̃1 (s.d.)
CR 0.796 458.1 (93.4) 0.500 (0.023)
DBCD 0.847 450.2 (99.9) 0.335 (0.021)
ERADE 0.838 450.9 (99.4) 0.334 (0.016)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure Power ENP (s.d.) ρ̃1 (s.d.)
CR 0.797 416.2 (86.1) 0.500 (0.023)
DBCD 0.837 404.5 (88.4) 0.334 (0.022)
ERADE 0.826 407.4 (88.3) 0.334 (0.017)
Fixed-sample design
Procedure Power ENP (s.d.) ρ̃1 (s.d.)
CR 0.805 500 (0) 0.501 (0.021)
DBCD 0.856 500 (0) 0.334 (0.019)
ERADE 0.855 500 (0) 0.334 (0.015)
Under the alternative hypothesis, from Table 2.2, a higher power is achieved by
the optimal response-adaptive randomised designs while using a lower ENP. For
instance, for (t1, t2, t3)=(0.5, 0.8, 1), the DBCD has around a 4% higher power
than CR, and reduces the ENP by about 12. For the group sequential designs
which allow early stopping, the ENP is significantly decreased compared to the
fixed-sample designs. However, the corresponding standard deviation of the ENP
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is large, since there are only three possible values that the ENP can take. More
specifically, for (t1, t2, t3)=(0.5, 0.8, 1), the number of patients can be 250, 400
or 500 when the trial stops at information time t1, t2 or t3, respectively. The
frequencies of the first two values are 807 and 2,174 for CR, 986 and 2,312 for the
DBCD, and 948 and 2,259 for the ERADE. The target Neyman allocation propor-
tion is well achieved for both optimal response-adaptive randomised designs, with
the ERADE consistently having a lower variability in the allocation proportion.
2.2.2. Binary responses
For binary responses, the optimal allocation derived by Rosenberger et al. (2001)
is used as the target optimal allocation. In addition, the expected number of
failures (ENF) is computed at the time when a decision is made. If a trial stops
early, the rest of the patients are assigned to the more promising treatment and
the total expected number of failures (ENF
′
) is obtained. Here, ENF
′
is provided
to compare with the ENF for the fixed-sample designs based on the maximum
sample size N . In practice, trials stop when a decision is made. The other simu-
lation settings are the same as in Section 2.2.1.
Under the null hypothesis, from Table 2.3, the type I error rate for all of the
designs is less than three standard errors away from 0.05, except for CR with
(t1, t2, t3)=(0.5, 0.8, 1), where a slightly conservative type I error rate, α̃ = 0.040,
is obtained. The differences in the ENP and the ENF between the group sequential
and the fixed-sample designs are small under H0. Both optimal response-adaptive
designs target well the optimal allocation proportion for arm 1 obtained from
(2.6). Here, the target allocation proportion for treatment 1 is ρ1 = 0.5 under the
null hypothesis. The ERADE consistently has a lower standard deviation for ρ̃1
among all designs.
Under the alternative hypothesis, from Table 2.4, the expected numbers of pa-
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Table 2.3.: Simulated type I error rate for two-armed binary trials with optimal
allocation in group sequential and fixed-sample designs, p1 = p2 =
0.5, N = 500.
(t1, t2, t3)=(0.2, 0.5, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃1 (s.d.)
CR 0.046 499.2 (14.8) 249.6 (13.6) 0.500 (0.021)
DBCD 0.048 499.2 (14.1) 249.9 (13.4) 0.500 (0.016)
ERADE 0.048 499.1 (15.4) 249.7 (13.7) 0.500 (0.012)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃1 (s.d.)
CR 0.040 497.4 (18.7) 248.8 (14.6) 0.500 (0.021)
DBCD 0.050 496.8 (21.0) 248.3 (15.4) 0.501 (0.016)
ERADE 0.050 497.0 (20.5) 248.6 (15.1) 0.500 (0.012)
Fixed-sample design
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃1 (s.d.)
CR 0.053 500 (0) 250.1 (11.0) 0.500 (0.022)
DBCD 0.053 500 (0) 250.1 (11.0) 0.500 (0.016)
ERADE 0.059 500 (0) 250.1 (11.0) 0.500 (0.011)
tients and failures can be significantly reduced using group sequential analysis
compared to the fixed-sample designs, despite the small treatment difference. For
example, for (t1, t2, t3)=(0.5, 0.8, 1), around 87 fewer patients on average are
used, and there is a reduction of about 37 in the ENF compared to the fixed-
sample designs. The power and the ENP for the response-adaptive designs are
similar to CR. However, there are about two fewer failures on average achieved by
the response-adaptive designs compared to CR. In addition, the optimal response-
adaptive randomisation procedures assign more patients to the better-performing
treatment. About 53% of the patients are allocated to treatment 2 with the higher
probability of success 62.5%.
Simulation results for other scenarios where the difference in the probabilities of
success is larger show similar conclusions. For binary responses, when the treat-
ment difference increases, the sample size decreases considerably. Only a small
number of failures is saved by using the response-adaptive designs instead of CR.
Also, the power and the ENP are comparable for CR, and the DBCD and the
ERADE.
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Table 2.4.: Simulated power for two-armed binary trials with optimal allocation in
group sequential and fixed-sample designs, p1 = 0.5, p2 = 0.625, N =
500.
(t1, t2, t3)=(0.2, 0.5, 1)
Procedure Power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃1 (s.d.)
CR 0.810 454.8 (96.4) 199.1 (43.4) 216.0 (12.1) 0.500 (0.023)
DBCD 0.809 454.6 (96.7) 197.3 (43.4) 214.3 (12.1) 0.470 (0.017)
ERADE 0.810 455.4 (96.0) 197.7 (43.1) 214.5 (11.9) 0.470 (0.013)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure Power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃1 (s.d.)
CR 0.799 413.8 (87.9) 181.1 (39.7) 213.5 (11.5) 0.500 (0.024)
DBCD 0.797 413.1 (88.4) 179.4 (40.1) 212.0 (11.5) 0.471 (0.017)
ERADE 0.796 413.8 (87.0) 179.6 (39.3) 211.9 (11.3) 0.470 (0.012)
Fixed-sample design
Procedure Power ENP (s.d.) ENF (s.d.) - - ρ̃1 (s.d.)
CR 0.814 500 (0) 218.9 (11.2) - - 0.500 (0.022)
DBCD 0.813 500 (0) 217.3 (11.2) - - 0.472 (0.015)
ERADE 0.814 500 (0) 217.2 (11.1) - - 0.472 (0.010)
2.2.3. Redesigning a placebo-controlled clinical trial
A multi-centre, placebo-controlled trial that investigated the efficacy of zidovudine
in reducing the risk of maternal-infant HIV transmission was studied by Connor
et al. (1994). A total number of 477 HIV-infected women were randomly assigned
to the experimental treatment or the placebo group with equal probabilities. Of
the 239 pregnant women receiving the experimental treatment, 8.3% of the infants
were HIV-infected, whereas 25.5% of the 238 from the placebo group were diag-
nosed as HIV positive.
A redesign of the placebo-controlled HIV trial using a group-sequential response-
adaptive design was investigated by Zhu and Hu (2010). The success probabil-
ities for the experimental treatment and the control group were assumed to be
p1 = 0.917 and p2 = 0.745, respectively. However, the authors focused on the
DBCD. Here, a comparison of different designs is made. Three group sequential
tests are planned at information times (0.2, 0.5, 1). The critical boundaries derived
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based on the linear spending function are used. The other simulation settings are
the same as in Section 2.2.2.
Table 2.5.: Simulated type I error rate for redesigning a two-armed binary trial
with optimal allocation, p1 = p2 = 0.745, N = 477.
(t1, t2, t3)=(0.2, 0.5, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃1 (s.d.)
CR 0.057 468.4 (50.8) 119.3 (16.0) 0.500 (0.022)
DBCD 0.055 469.1 (48.5) 119.5 (15.5) 0.500 (0.014)
ERADE 0.054 469.9 (45.9) 119.8 (15.0) 0.500 (0.008)
Table 2.5 shows that, under the null hypothesis, the critical boundaries can control
the overall type I error rate for all of the designs. The ENP, the ENF and ρ̃1 are
similar for the response-adaptive and non-adaptive designs.
Table 2.6.: Simulated power for redesigning a two-armed binary trial with optimal
allocation, p1 = 0.917, p2 = 0.745, N = 477.
Procedure Power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃1 (s.d.)
CR 0.9992 209.8 (111.0) 35.4 (18.6) 57.6 (10.1) 0.499 (0.031)
DBCD 0.9992 212.0 (111.9) 34.9 (18.3) 56.9 (9.7) 0.526 (0.020)
ERADE 0.9996 211.0 (107.7) 34.6 (17.6) 56.7 (9.4) 0.529 (0.011)
Under the alternative hypothesis, from Table 2.6, a high power is achieved for all
of the designs. In Zhu and Hu (2010), the powers are 0.999 and 0.997 for CR
and the DBCD, respectively. This means that the difference in treatment effects
can be easily detected. The optimal allocation (Rosenberger et al., 2001) aims
to minimise the total expected number of failures. However, here just marginal
decreases in the ENF and the ENF
′
are shown for the DBCD and the ERADE
compared to CR. Although the response-adaptive designs achieve a lower number
of failures while using a slightly larger number of patients, there is not much gain
compared to the CR design. Hence, in this case, use of the group-sequential CR
design is preferred.
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2.3. Extension to censored survival responses
2.3.1. Information time
Maximum information trials consider a pre-determined target information level.
The information level for survival responses is proportional to the number of
events. A trial continues until the maximum information level is achieved. How-
ever, for survival responses, the outcomes such as death are often unpredictable,
and depend on the recruitment rate, censoring and so on. A trial may not achieve
the required information level at the end of the study, or the information level may
be attained soon after the trial begins. In these cases, a maximum duration trial,
where the maximum length of the trial is pre-determined, may be more feasible
in practice.
For maximum duration trials, the number of events at the final look is not known
until the trial reaches the end of the study. Hence, at each interim analysis, a pre-
dicted value for the final information level evaluated at look k, Î(k)K , k = 1, ..., K,
is needed. Then the information time for survival responses at group sequential










where ek is the observed number of events at look k and ê
(k)
K is the expected total
number of events evaluated at that look (Jennison and Turnbull, 2000).







, if k < K and ek ≤ ê(k)K ,
1, otherwise.
(2.10)
They explained that the total expected number of events can be estimated based
on the assumed survival model. However, there are two candidates for the esti-
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mate of eK . One is under the null hypothesis of no treatment difference and the
other is based on the specified alternative hypothesis. Kim et al. (1995) showed
that the overall type I error rate can be preserved under both hypotheses for a
logrank test. The power depends on the actual information level obtained.










, k = 1, ..., K,
where mj,k is the cumulative sample size for treatment j at look k and ε̂j,k is the
probability of an event for treatment j evaluated at look k, which depends on
the assumed models. For uniformly distributed arrival and censoring times, and























where D is the maximum duration of the trial. Details of the derivation are pro-
vided in Appendix A. The probability of an event increases as the length of the
trial is increased. Also, for group sequential designs, εj,k is larger at later looks
than at early ones. More specifically, as D and/or tk increase, the probability
of an event is increased. Since the εj,k are functions of unknown parameters, for
the first look when k = 1, initial parameter estimates from a previous study or
obtained in the learning phase using permuted-block randomisation can be used.
Then the parameter estimates based on the cumulative responses can be used for
k ≥ 2.
As mentioned above, there are two candidates for the estimated number of events,
which result in two information time scales. The type I error rate can be guaran-
teed by using either information time scale (Kim et al., 1995). For simplicity, we
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consider the estimated number of events, êk, under the assumption that the null
hypothesis is true (θ1 = θ2). Then the subscript j for εj,k denoting treatment can













∈ (0, 1], k = 1, ..., K. (2.12)
In (2.9) and (2.10), tk = 1 can occur if k ≤ K. However, in (2.12), tk = 1 occurs
only when k = K. That is, for a maximum duration trial, the type I error rate
will be spent only when the trial reaches the maximum length of the study. The
error-spending approach can be used to control the overall type I error rate. Now
suppose that we wish to conduct the first interim analysis when about one third
of the expected total number of events is obtained. Then the first interim analysis
is planned at t1 = 1/3, and, from (2.12), n1 = dt1Nε̂K/ε̂1e is the approximate
number of patients needed at the first look.
Here, ε̂k, k = 1, ..., K, is an estimate based on the sample. The accuracy of
the parameter estimates increases when the sample size is increased. At early
looks with small sample sizes, the approximate information level in (2.12) can be
inaccurate. Any deviations between the observed and target information levels
may affect the type I error rate. However, the use of the O’Brien and Fleming
test can alleviate the issue, since little type I error rate is spent during the early
stages. In addition, related work of Proschan et al. (1992) and Jennison and Turn-
bull (2000) investigated the effect of applying critical boundaries derived based on
equally spaced information levels to the actual observed unequal information se-
quence. It was found that the maximum increase in the type I error rate seems to
be robust under various scenarios of departure from equal group sizes.
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2.3.2. Model assumptions
The proposed group-sequential response-adaptive design for survival responses
allows staggered entry and takes into account the issue of right-censoring. Let D
be the length of a maximum duration trial. The information times t0 = 0 and
tK = 1 refer to the commencement and the end of the trial, respectively. Suppose
that group sequential tests take place at information time tk ∈ (0, 1], k = 1, ..., K.
Then the calendar time at which the kth interim analysis occurs can be expressed
as Dtk. Assume that patient arrival time is uniformly distributed. The arrival
time for patient i who arrived before or at the kth look is Ai ∼ U(0, Dtk). Assume
that the survival time for patient i on treatment j, Si,j, follows an exponential









for si,j > 0.
The survival function, which is the probability that the time of an event will be
later than si,j, is






and the hazard rate for treatment j is θ−1j . In addition, the censoring time for
patient i, Ci, is assumed to be uniformly distributed from zero to D. Here, the
treatment groups are assumed to have the same arrival and censoring time distri-
butions. Patients’ arrival, survival and censoring times are assumed to be inde-
pendent of each other.
Under the above model assumptions, the observed survival response for patient
i, i = 1, ...,mj,k, on treatment j, j = 1, 2, at group sequential test k, k = 1, ..., K,
can be expressed as Yi,j,k = min(Si,j, Ci, Dtk − Ai). Here, the duration of the
trial, D, and the arrival time of patient i, Ai, start from the beginning of the study,
while the survival time Si,j and the censoring time Ci commence from the arrival
of that patient. For example, suppose that the number of group sequential tests
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is K = 3. At the first interim analysis, we have Yi,j,1 = min(Si,j, Ci, Dt1 − Ai),
where Ai ∼ U(0, Dt1).
Figure 2.1.: An example of a patient’s arrival time, survival time and censoring
time
If Yi,j,1 = Si,j, then the patient’s response is an event. If Yi,j,1 = Ci, then the
patient’s response is right-censored due to loss to follow up. If Yi,j,1 = Dt1 − Ai,
then the outcome is right-censored because the patient has not yet responded at
the first look. The patient’s response will then be followed up at later looks. Let
Ei,j = min(Si,j, Ci). If the response occurs between the first and the second looks,
then Dt1 < Ai + Ei,j ≤ Dt2 and we have Yi,j,2 = Ei,j. An example is shown in
Figure 2.1, where Ei,j = Si,j and Yi,j,2 = Si,j. If Dt2 < Ai + Ei,j ≤ Dt3, then we
have Yi,j,2 = Dt2 − Ai and Yi,j,3 = Ei,j. If the patient has not responded by the
end of the trial, then Ai +Ei,j > Dt3, Yi,j,2 = Dt2−Ai and Yi,j,3 = Dt3−Ai. Sim-
ilarly, at the second interim test, we have Yi,j,2 = min(Si,j, Ci, Dt2 − Ai), where
Ai ∼ U(0, Dt2). If Yi,j,2 = Dt2 − Ai, then we follow up the response at the next
look. If Dt2 < Ai + Ei,j ≤ Dt3, then Yi,j,3 = Ei,j. Otherwise, Yi,j,3 = Dt3 − Ai.
For the final look, however, no response will be followed up.
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Likelihood function, point estimate and variance
Suppose that two independent random samples {yi,j,k, δi,j,k, i = 1, . . . ,mj,k} for
treatment j, j = 1, 2, are obtained. Here, δi,j,k = 1 if the response of patient i on
arm j at look k is an event and δi,j,k = 0 if the response is censored. Under the
above model, the likelihood function of θj for treatment j based on the responses


















where the first part of the product in (2.13) refers to the survival times and the
second part represents the censoring times. The log-likelihood function is


















for a maximum. Hence, we obtain the maximum likelihood estimate of the mean






which is the sum of the observed survival times divided by the number of events
obtained so far.

























Here, if there were no censored data,
∑mj,k
i=1 Yi,j,k ∼ Γ(mj,k, θ−1j ). However, if
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there is censoring, then
∑mj,k
i=1 Yi,j,k ∼ Γ(rj,k, θ−1j ) and E(
∑mj,k
i=1 Yi,j,k) can be ap-
proximated by θjE(rj,k) (Cox and Oakes, 1984). So the Fisher information is
approximately






as the approximate variance of θ̂j,k for treatment j evaluated based on the cumu-
lative responses.
2.3.3. Test statistic
Consider the parameter of interest as the difference in the mean survival times for
the two treatments, φ = θ1 − θ2. The null hypothesis is H0 : φ = 0 versus the
alternative hypothesis Ha : φ 6= 0. Suppose that φ̂k = θ̂1,k − θ̂2,k is the maximum
likelihood estimate of φ at look k. Under the assumption that the responses on
the two arms are independent, we obtain
var(φ̂k) = var(θ̂1,k − θ̂2,k) = I(θ1)−1 + I(θ2)−1 = θ21/E(r1,k) + θ22/E(r2,k).
Based on the assumed model, E(rj,k) can be approximated by mj,kεj,k, where mj,k
is the sample size on treatment j at look k and εj,k is the probability of having an
event. In practice, the observed number of events on arm j at look k, rj,k, is used.








, k = 1, ..., K. (2.14)
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The test statistic (2.14) is approximately normal for large sample sizes. Note that
it cannot be calculated until there is at least one event on both treatment arms,
so that rj,k > 0, j = 1, 2.
2.3.4. Optimal response-adaptive randomisation
Although survival responses are usually not immediately available after the treat-
ments are assigned, the optimal response-adaptive randomisation procedures de-
scribed in Section 2.1.2 can still be applied, provided that some responses have
been obtained. In fact, Zhang and Rosenberger (2007) showed that a moderate
delay in censored survival responses has only a modest effect on the asymptotic
properties of the DBCD. Here, some optimal allocations for censored survival re-
sponses discussed in Zhang and Rosenberger (2007) are introduced.
Neyman allocation
For the test statistic considered, Neyman allocation is found by minimising the
total sample size M1 + (N − M1) with respect to M1 under a variance con-
straint, θ21/E(r1) + θ
2
2/E(r2) = C, where the expected number of events on arm j,










and ρ2 = 1− ρ1.
Optimal allocation
For survival responses, optimal allocation aims to minimise the total expected
hazard, M1θ
−1
1 + (N − M1)θ−12 , with respect to M1 under the above variance







and ρ2 = 1− ρ1. (2.15)
Here, the optimal allocation proportions are functions of the unknown parameters.
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In addition, the probability of an event on treatment j, εj, which depends on the
assumed models, is also a function of the unknown parameters, as shown in (2.11).
In practice, the current parameter estimates based on the responses available are
used. Then the estimated target optimal allocation proportion for treatment 1
can be used in the DBCD and ERADE functions in Section 2.1.2 to obtain the
allocation probability for the next patient.
2.3.5. Simulation study
Consider the model assumptions described in Section 2.3.2. We wish to compare
the two survival means using test statistic (2.14). Similar parameter settings are
used as in Rosenberger and Seshaiyer (1997) and Zhang and Rosenberger (2007).
The duration of the trial is D = 1.5936. The maximum sample size N = 800 is
chosen to achieve around 80% power. Here, the optimal allocation that minimises
the total expected hazard for censored survival responses is applied. The other
simulation settings are the same as in Section 2.2.2.
As can be seen in Table 2.7, the type I error rate for all of the designs is within 0.01
deviation from the pre-specified value, 0.05. A slightly conservative α̃ is obtained
for CR, which is within three standard errors of 0.05. For the response-adaptive
designs, α̃ usually lies within 1-3 standard errors of 0.05. For (t1, t2, t3)=(0.5, 0.8,
1), the value of α̃ for the ERADE is just outside of the range of three standard
errors, (0.041, 0.059). The results reveal that, in general, the analogous O’Brien
and Fleming boundaries derived by the error-spending approach based on normal
responses can be applied as an approximate result to censored survival responses.
Under the null hypothesis, the target optimal allocation yields equal allocation,
and hence the expected number of patients (ENP) and the expected number of fail-
ures (ENF) are similar across designs. However, the use of the response-adaptive
designs seems to increase the variability in the allocation proportion compared to
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Table 2.7.: Simulated type I error rate for two-armed censored survival trials with
optimal allocation in group sequential and fixed-sample designs, θ1 =
θ2 = 1, N = 800.
(t1, t2, t3)=(0.2, 0.5, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃1 (s.d.)
CR 0.043 799.9 (4.8) 298.0 (1.8) 0.500 (0.017)
DBCD 0.052 798.9 (15.8) 297.6 (5.9) 0.501 (0.059)
ERADE 0.051 798.8 (16.9) 297.6 (6.3) 0.500 (0.052)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃1 (s.d.)
CR 0.041 797.7 (15.9) 297.1 (5.9) 0.500 (0.017)
DBCD 0.057 796.2 (24.2) 296.6 (9.0) 0.501 (0.062)
ERADE 0.060 796.0 (24.1) 296.5 (9.0) 0.501 (0.054)
Fixed-sample designs
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃1 (s.d.)
CR 0.042 800 (0) 298.0 (0) 0.500 (0.017)
DBCD 0.055 800 (0) 298.0 (0) 0.501 (0.059)
ERADE 0.052 800 (0) 298.0 (0) 0.500 (0.053)
CR. The standard deviations of ρ̃1 for the DBCD and the ERADE are just over
three times higher than for CR.
Under the alternative hypothesis, from Table 2.8, the use of optimal response-
adaptive randomisation significantly reduces the ENF for both group sequential
and fixed-sample designs compared to CR. For the group sequential designs, we
also have a lower ENP for the response-adaptive randomised designs than for CR.
Moreover, the power is not adversely affected and can be higher in the response-
adaptive randomised designs. For example, for (t1, t2, t3)=(0.2, 0.5, 1), the power
for the ERADE is increased by around 1% compared to CR, while using 17 fewer
patients and reducing the number of failures by about 10.
Here, the optimal allocation proportion for treatment 1, ρ1, calculated from (2.15)
is 0.652. The average allocation proportion, ρ̃1, for the DBCD and the ERADE
is within 0.01 deviation from ρ1. In addition to the high accuracy in targeting
the optimal allocation proportion, a reasonably small standard deviation for ρ̃1 is
achieved, with the ERADE consistently having a lower variability than the DBCD.
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Table 2.8.: Simulated power for two-armed censored survival trials with optimal
allocation in group sequential and fixed-sample design, θ1 = 1.4, θ2 =
1, N = 800.
(t1, t2, t3)=(0.2, 0.5, 1)
Procedure Power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃1 (s.d.)
CR 0.815 767.7 (81.7) 255.1 (27.2) 264.5 (3.5) 0.500 (0.017)
DBCD 0.823 749.7 (97.5) 240.0 (33.6) 254.7 (5.9) 0.656 (0.070)
ERADE 0.826 750.4 (96.9) 240.4 (33.1) 254.9 (5.5) 0.652 (0.061)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure Power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃1 (s.d.)
CR 0.808 730.5 (64.3) 242.7 (21.4) 263.0 (2.8) 0.500 (0.018)
DBCD 0.805 717.5 (78.9) 229.7 (28.4) 253.8 (5.8) 0.657 (0.070)
ERADE 0.821 715.9 (79.2) 229.1 (28.3) 253.7 (5.5) 0.658 (0.064)
Fixed-sample designs
Procedure Power ENP (s.d.) ENF (s.d.) - - ρ̃1 (s.d.)
CR 0.769 800 (0) 265.8 (1.1) - - 0.500 (0.017)
DBCD 0.779 800 (0) 256.0 (3.8) - - 0.653 (0.060)
ERADE 0.775 800 (0) 256.1 (3.5) - - 0.651 (0.054)
Compared to the fixed-sample designs, the group sequential designs clearly have a
lower ENP due to early stopping under Ha, and hence a reduced ENF is obtained.
As mentioned previously, the quantity ENF
′
for the group sequential designs is
computed to compare with ENF for the fixed-sample designs based on the max-
imum sample size N . If a decision for early termination is made, the rest of the
patients are assigned to the better-performing treatment arm. Here, a slightly
lower ENF
′
than the ENF is obtained. For instance, for (t1, t2, t3)=(0.5, 0.8, 1),
there are about three fewer failures on average for the group-sequential response-
adaptive designs than for the fixed-sample response-adaptive designs.
2.4. Conclusions
The combined approach of group sequential analysis with optimal response-adaptive
randomisation has been studied and shown to be more ethical in terms of reducing
the average sample size and the expected number of failures for binary responses.
A generalisation of the combined approach to censored survival responses using
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an estimate of the information time based on the model assumed is studied in
this chapter. Then critical boundaries derived using the error-spending approach
can be applied to the designs. The simulation results reveal that incorporating
adaptive sampling rules in group sequential designs also preserves the error rates
while assigning more patients to the more promising treatment.
Both optimal response-adaptive randomisation procedures target the pre-specified
desired allocation well with reasonably small variability. Among the response-
adaptive designs, the ERADE consistently has a lower standard deviation for the





dropping of inferior arm(s)
3.1. Form of test
3.1.1. Information time
Let N be the maximum number of patients for a trial with K group sequential
analyses and let J be the number of arms. For normal and binary multi-armed












∈ (0, 1], k = 1, ..., K,
where Ik denotes the information level at group sequential test k, mj,k is the cumu-
lative number of observations for treatment j, j = 1, ..., J, at look k, mj,K = Mj,
and nk =
∑J
j=1mj,k is the cumulative sample size at look k, nK = N . Here, the
formula for the information time has the same form as (2.1) for two-armed trials.
For censored survival responses, the information level is proportional to the num-
ber of events. Consider the approximate information level described in Section
– 41 –
3. Adaptive designs for multi-armed trials without dropping of inferior arm(s)












where êk is the estimated number of events at look k, which depends on the
model assumptions. As mentioned in Section 2.3.1, there are two candidates for
the estimate of ek. One is under the null hypothesis and the other is under a
specified alternative hypothesis. The overall type I error rate can be controlled
in either case (Kim et al., 1995). For simplicity, the estimate of ek under the
null hypothesis, where the parameters are all equal, is considered. Then the








∈ (0, 1], k = 1, ..., K.
Here, the subscript j for ε̂j,k denoting the treatment is suppressed, since the pa-
rameters are all equal.
3.1.2. Global test statistics
Normal responses with a common variance
Consider testing the homogeneity of J normal means with a common variance
σ2. We wish to test the global null hypothesis HG0 : µ1 = ... = µJ versus the
alternative hypothesis HGa : ¬HG0 . This testing problem has been studied by
Jennison and Turnbull (1991, 2000). For equal allocation, the global test statistic






(Ȳj,k − Ȳ.k)2, k = 1, ..., K,
where mk is the cumulative sample size on each arm at look k, Ȳj,k is the sample
mean of the cumulative responses on treatment j at look k and Ȳ.k =
∑J
j=1 Ȳj,k/J
is the overall mean based on the responses obtained so far. The test statistic Sk is
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essentially the standardised between-arms sum-of-squares statistic. The marginal
distribution of Sk is exactly χ
2 with J − 1 degrees of freedom under HG0 . Under






(µj − µ̄)2, k = 1, ..., K,
where µ̄ = (µ1 + ...+ µJ)/J . The noncentrality parameter ηk increases as the cu-
mulative sample size mk is increased. In other words, the noncentrality parameter
and the power of tests increase in later looks with a larger cumulative sample size.







mj,k(Ȳj,k − Ȳ.k)2, k = 1, ..., K, (3.1)










For optimal response-adaptive randomisation, the sample size for treatment j at
look k, mj,k, is random . However, it can be approximated, since the allocation
proportions converge almost surely to the pre-specified optimal allocation propor-
tions (Hu and Zhang, 2004). We have mj,k = ρj
∑J
j=1mj,k = ρjnk approximately.
The marginal distribution of Sk in (3.1) is asymptotically χ
2 with J − 1 degrees
of freedom under HG0 , provided that the unbalanced allocation is not too severe.
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Normal responses with a pooled variance estimate
In practice, σ2 is usually unknown. A pooled sample variance can be used as an




(J − 1) S2k
J∑
j=1
(Ȳj,k − Ȳ.k)2, k = 1, ..., K,













Here, Fk ∼ Fv1,v2 with v1 = J − 1 and v2 = J(mk − 1) under HG0 (Jennison and
Turnbull, 1991, 2000).
For optimal response-adaptive randomisation where treatment allocation is usu-
ally unequal, the test statistic is
Fk =
1
(J − 1) S2k
J∑
j=1












As long as the unbalanced treatment allocation is not too severe, the test statistic
is asymptotically F distributed with degrees of freedom v1 = J − 1 and v2 =
J(m.k − 1) under HG0 , where m.k =
∑J
j=1mj,k/J can be used.
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Normal responses with unequal variances
For equal allocation, Proschan et al. (1994) used the following chi-squared statistic
for testing homogeneity:
Sk = (Z1,k, ..., ZJ−1,k)Σ̂
−1
k (Z1,k, ..., ZJ−1,k)
T , k = 1, ..., K,
where Zj,k, j = 1, ..., J − 1, is the standardised normal statistic for comparing
treatment j with the average of the other arms. For example,
Z1,k = {Ȳ1,k − (Ȳ2,k + ...+ ȲJ,k)/(J − 1)}/
√
ˆV1,k,
with V̂1,k = {σ̂21,k+(σ̂22,k+ ...+ σ̂2J,k)/(J−1)2}/mk. Also, Σ̂k is the (J−1)× (J−1)
estimated covariance matrix of (Z1,k, ..., ZJ−1,k) at look k. Here, arm J is omitted
to prevent the issue of singularity. One may choose to leave out any treatment j
and the same value of the test statistic will be obtained.
Now suppose that we wish to test HG0 : µG = 0 versus HGa : µG 6= 0, where
µG = (µ1− µJ , µ2− µJ , ..., µJ−1− µJ)T is a vector of treatment contrasts taking





Σ̂−1k µ̂Gk , k = 1, ..., K, (3.2)
where µ̂Gk = (Ȳ1,k− ȲJ,k, Ȳ2,k− ȲJ,k, ..., ȲJ−1,k− ȲJ,k)
T is the maximum likelihood
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Here, 1 = (1, ...., 1)T is the vector with J − 1 ones. In addition, Σ̂k is nonsingular
and its inverse exists.





Σ̂−1k µ̂Gk) ' E{(V + µG)
TΣ−1k (V + µG)}














Let Z = Σ
−1/2
k V ∼ NJ−1(0, IJ−1). Then we have
E(Sk) ' E(ZTZ) + µTGΣ−1k µG
= J − 1 + µTGΣ−1k µG.
Under HG0 , the marginal distribution of Sk is asymptotically χ
2 with J − 1 de-
























The proof of (3.4) is given in Appendix B.
Binary responses
Suppose that we wish to test the global null hypothesis HG0 : pG = 0 versus
HGa : pG 6= 0, where pG = (p1 − pJ , p2 − pJ , ..., pJ−1 − pJ)T is the vector of
treatment contrasts of the probabilities of success. The testing problem for optimal
response-adaptive randomisation in a fixed-sample design has been discussed by





Σ̂−1k p̂Gk , k = 1, ..., K, (3.5)
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where p̂Gk is the maximum likelihood estimator of pG based on the responses



















Since the test statistic (3.5) is a quadratic form in asymptotically normal variables,
the marginal distribution of Sk is asymptotically χ
2 with J −1 degrees of freedom
























The derivation of (3.6) is similar to the normal responses case. In addition, the
derived noncentrality parameter ηk has the same form as the one obtained by
Tymofyeyev et al. (2007) in a fixed-sample design. Therefore, (3.6) possesses the
same properties. For example, it is a concave function and ∂ηk/∂mj,k ≥ 0. When
the cumulative number of patients on any treatment arm, mj,k, j = 1, ..., J, in-
creases, ηk is increased.
Censored survival responses
Proschan et al. (1994) and Follmann et al. (1994) demonstrated group sequential
monitoring multi-armed survival trials using a nonparametric logrank statistic.
The work considered equal allocation or fixed unequal allocation determined be-
fore commencing the trial. Using a parametric approach, Sverdlov et al. (2011)
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investigated the implementation of optimal response-adaptive randomisation in
multi-armed censored survival trials in a fixed-sample design. In this section, an
extension of the work of Sverdlov et al. (2011) to group sequential designs is stud-
ied.
Sverdlov et al. (2011) considered the same model assumptions as described in
Section 2.3.2. The observed survival response for patient i, i = 1, ...,mj,k, on
treatment j, j = 1, ..., J, at look k, k = 1, ..., K, can be expressed as Yi,j,k =
min(Si,j, Ci, Dtk − Ai), where D is the duration of the trial and tk is the in-
formation time at look k. As shown in Section 2.3.2, we have the maximum
likelihood estimate of the mean survival time for treatment j evaluated at look
k, θ̂j,k =
∑mj,k
i=1 yi,j,k/rj,k, and var(θ̂j,k) = θ
2
j/E(rj,k), where rj,k is the cumulative
number of events on treatment j at look k.
Consider testing the vector of treatment contrasts of J survival means. Then
the global null hypothesis is HG0 : θG = 0 versus HGa : θG 6= 0, where θG =




Σ̂−1k θ̂Gk , k = 1, ..., K, (3.7)



















Again, the marginal distribution of Sk is asymptotically chi-squared with J − 1
degrees of freedom under HG0 . Under HGa , the distribution is asymptotically non-
central chi-squared with noncentrality parameter
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which is derived in a similar way to the normal and binary responses cases.
3.1.3. Stopping boundaries
For the global tests, the joint distribution of the sequence of test statistics {S1, ..., SK}
does not have the standard canonical joint distribution (Jennison and Turnbull,
2000). However, for normal responses and equal variances with equal allocation,
Jennison and Turnbull (1991) showed that the sequence of test statistics is Markov.
More specifically, the probability distribution of Sk+1 depends only on Sk and not
on {S1, ..., Sk−1}. The joint distribution of {S1, ..., Sk+1} can be constructed re-
cursively by multiplying the conditional distributions of Sk+1 given Sk for k ≥ 1.
Based on the joint distribution, the exact critical boundaries can be obtained re-
cursively. The boundaries analogous to Pocock’s and the O’Brien and Fleming
boundaries can be found in Jennison and Turnbull (1991, 2000). For the unknown
variance case, sequential F statistics are used. The critical boundaries for this
case can also be obtained from Jennison and Turnbull (1991).
For the cases of unequal variances and unbalanced sample sizes across treatments,
the exact critical boundaries are not available. One approach is to compute them
by simulation. The joint distribution of {S1, ..., SK} can be obtained numerically
because Sk is a quadratic form in asymptotically normal variables with known
covariances. Consider the normal responses case as an example. Then the covari-
ance of Xj,k and Xj′ ,k′ , where Xj,k = Ȳj,k − ȲJ,k, for 1 ≤ j ≤ j
′ ≤ J − 1 and
1 ≤ k < k′ ≤ K is
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if j 6= j ′ .
Alternatively, the significance level approach (Jennison and Turnbull, 2000) can
be used to give an approximate test, as long as the imbalance in the sample sizes
is not too severe. In this case, the critical boundaries derived based on equal
variances and equal allocation (Jennison and Turnbull, 1991, 2000) are applied to
the actual observed responses to give an approximate test.
The stopping rule for multi-armed clinical trials without allowing dropping of
inferior treatments is given below.
• Stop the trial and reject HG0 the first time that Sk ≥ dk.
• Accept HG0 if SK < dK at the final stage.
3.2. Optimal response-adaptive randomisation
3.2.1. Optimal allocations
In this section, two optimal allocations for multi-armed trials are introduced. One
ensures the most efficient estimates of the treatment effects and the other aims
to maximise the power subject to a fixed total sample size. The two optimal
allocations reduce to Neyman allocation when J = 2. However, for J ≥ 3, they
have different characteristics.
DA-optimal allocation
Most of the optimal allocations are derived for homoscedastic models which as-
sume a constant variance for the responses across treatments. In this case, the
equal allocation rule is optimal in terms of efficiency. However, for heteroscedastic
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models, an unbalanced allocation can be more efficient. Wong and Zhu (2008) de-
rived the DA-optimal allocation for multi-armed normal trials using a fixed-sample
design. Assume that the responses are based on the heteroscedastic model
Y = fT (x)β + ε.
Here, x = (x1, ..., xJ)
T and the jth element, xj, indicates arm j. For treatment j,
f(xj) is a zero vector with the jth element replaced by one, and β is the vector
of parameters. The vector ε is assumed to be multivariate normal with zero mean
vector and a diagonal covariance matrix, under the assumption that the responses
from different treatment arms are independent. Let the variance of the responses
on treatment j be σ2/w(xj), where w(xj) is inversely proportional to the vari-
ance of the responses on arm j and assumed known. Without loss of generality,
the case σ2 = 1 is considered. The variance for treatment j then becomes 1/w(xj).
Let ρj be the allocation proportion for treatment j. A randomisation design ξ









w(x1)ρ1 0 ... 0
0 w(x2)ρ2 ... 0
. . .
. . .




Suppose that the parameter of interest is the vector of treatment contrasts ATβ =
(β1− βJ , ..., βJ−1− βJ)T , where AT is a (J − 1)× J matrix. Then the DA-optimal
allocation ensures the most precise estimate of ATβ. The solution to the optimal
allocation is obtained by minimising the determinant of cov(AT β̂) = ATM−1(ξ)A,
where β̂ is the maximum likelihood estimator of β, over all possible randomisa-
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tion designs ξ, or, equivalently, by minimising its logarithm. Then the optimal
rule is to minimise Φ(ξ) = log|ATM−1(ξ)A|. The DA-optimal allocation yields
the smallest confidence ellipsoid for ATβ.
In practice, one can use the general equivalence theorem (GET) (Kiefer and
Wolfowitz, 1960) to obtain the DA-optimal allocation by solving the system of
equations
dA(xj, ξ
∗) = J − 1, j = 1, ..., J,
where dA(xj, ξ
∗) is the directional derivative of the criterion Φ(ξ∗), ξ∗ is the opti-







, j = 1, ..., J,
as derived by Wong and Zhu (2008).
Sverdlov et al. (2011) generalised the DA-optimal allocation to censored survival
responses. For exponentially distributed survival responses, the solution is ob-












= J − 1, j = 1, ..., J,
where θj is the mean survival time for treatment j, εj is the probability of an event
on arm j and εj/θ
2
j is inversely proportional to the variance for arm j.







= J − 1, j = 1, ..., J, (3.9)
where 1/(pjqj) is inversely proportional to the variance for treatment j.
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The DA-optimal design consistently allocates more patients to the treatments
that have larger variances for the responses. For exponentially distributed sur-
vival responses, the variance of the responses on arm j is θ2j/E(rj), as shown in
Section 2.3.2. In this case, the variance increases when the mean survival time for
treatment j, θj, is increased. Therefore, for exponential survival responses, the
DA-optimal allocation is always ethical (Sverdlov et al., 2011). However, for nor-
mal and binary responses, the most efficient design may assign more patients to
the inferior treatments. The optimal allocation depends on the unknown parame-
ters. In practice, the current parameter estimates are updated after each response.
The DA-optimal allocation proportion, ρj, j = 1, ..., J , satisfies 0 ≤ ρj ≤ 1/(J−1).
When the number of treatments is J = 2, the DA-optimal allocation reduces to
Neyman allocation. For J ≥ 3, the solution has no closed form. However, it can
be computed numerically by finding the root of the system of nonlinear equations.
The R package rootSolve, which utilises the Newton-Raphson method, can be used.
Optimal allocations based on nonlinear programming
The process for solving an optimality problem, which maximises or minimises an
objective function with equalities or inequalities as constraints, where the objective
function or some of the constraints are nonlinear, is called nonlinear programming.
To find a design that maximises the power of test, one can consider maximising
the noncentrality parameter η (as shown in Section 3.1.2) since the power increases
as η is increased. In this case, we have nonlinear objective function because η is a
nonlinear function of the sample size.
Tymofyeyev et al. (2007) considered the following optimality problems for multi-
armed binary trials with a fixed-sample design: (a) maximising the power of the
test of homogeneity, subject to the constraint that the weighted sum of the sample
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sizes does not exceed a positive constant C, and also subject to a user-specified
lower bound, B, for the allocation proportion ρj, j = 1, ..., J ; (b) minimising the
weighted sum of the sample sizes for a fixed power. The authors showed that
the two optimality problems yield the same solution. The optimality rule can be
expressed as
(a) maximise the noncentrality parameter η such that
J∑
j=1
vjMj ≤ C and
Mj
N
≥ B, for j = 1, ..., J,
(3.10)
where (v1, ..., vJ) is a vector of some positive weights, Mj is the sample size for
treatment j,
∑J
j=1Mj = N and the lower bound B ∈ [0, 1/J ]. By selecting B > 0,





η ≥ C and Mj
N
≥ B, for j = 1, ..., J.
When the vector of weights (v1, ..., vJ) = (1, ..., 1) and B = 0, the solution
maximises the power subject to the constraint that the total sample size does
not exceed a fixed value, which is an analogue of Neyman allocation. When
(v1, ..., vJ) = (q1, ..., qJ), where qj is the failure probability for treatment j, the
derived optimal allocation minimises the expected number of failures for a fixed
power, which is an analogue of the optimal allocation derived by Rosenberger et al.
(2001) generalised to J ≥ 3 treatments. A general solution (ρ1, ..., ρJ) for any vec-
tor of weights does not exist. Tymofyeyev et al. (2007) provided a closed form for
the solution for the case when (v1, ..., vJ) = (1, ..., 1), which is given below. For
other cases, numerical methods are required to obtain the solution.
Let the success probabilities be p1 = ... = ps > ps+1 ≥ ... ≥ pJ−g > pJ−g+1 =
... = pJ for some positive integers s and g. For instance, for three-armed trials,
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s = g = 1. This assumption is needed to specify the multiplicities of the highest
and lowest values of the underlying success probabilities.
(i) When B ∈ [0, B̃], B̃ = min(B̃1, B̃J , 1/J), the optimal allocation based on
nonlinear programming (NP) is (ρ1, ..., ρJ) with












ρs+1 = ... = ρJ−g = B,
ρJ−g+1 = ... = ρJ =
1
g











































(ii) When B > B̃ and B̃ = B̃1, the vector of optimal allocation proportions is
ρ =(B, ..., B, ρJ−g+1, ..., ρJ)
with ρJ−g+1 = ... = ρJ =
1− (J − g)B
g
.
(iii) When B > B̃ and B̃ = B̃J , the solution is
ρ =(ρ1, ..., ρs, B, ..., B)
with ρ1 = ... = ρs =
1− (J − s)B
s
.
In cases (ii) and (iii), the optimal allocation proportions are fixed as shown above.
In case (i), the optimal allocation proportions for treatments other than the best
and the worst ones are fixed at the lower bound, that is, ρs+1 = ... = ρJ−g = B,
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whereas the best and worst treatment allocation proportions depend on the un-
known parameters. In practice, the parameter estimates are used.
When B = 0, the solution maximises the power. However, patients are assigned
to the best and the worst treatments only. When B = 1/J , the solution becomes
equal allocation by definition. Tymofyeyev et al. (2007) pointed out that, although
theoretically the power increases as B decreases, in practice, the increase in the
variability of the allocation proportions has an adverse effect on the power for
small values of B. For trials with J = 3 arms, the authors took B = 0.25 to give
a reasonably small variability in the allocation proportions while preserving the
power. In addition, they observed by simulation that a choice of B = 0.1, 0.2 and
0.25 does not affect the conclusions when comparing the power of the response-
adaptive design to the CR design.
Sverdlov et al. (2011) generalised NP to censored survival responses. Assume
that the order of the J mean survival times is θ1 = ... = θs > θs+1 ≥ ... ≥ θJ−g >
θJ−g+1 = ... = θJ for some positive integers s and g.
(i) When B ∈ [0, B̃], B̃ = min(B̃1, B̃J , 1/J), the solution becomes















ρs+1 = ... = ρJ−g = B,
ρJ−g+1 = ... = ρJ =
1
g

























































For case (ii) when B > B̃ and B̃ = B̃1, and case (iii) when B > B̃ and B̃ = B̃J ,
the optimal allocation proportions are fixed and identical to the binary case.
When J = 2, both the DA-optimal allocation and the optimal allocation based
on NP with (v1, ..., vJ) = (1, ..., 1) reduce to Neyman allocation. However, when
J ≥ 3, they are quite different (Sverdlov et al., 2011). The authors compared
the DBCD targeting DA-optimal allocation and NP allocation by simulation for
three-armed censored survival trials in a fixed-sample design. It was found that
the design targeting NP allocation attained a higher power than those using the
DA-optimal allocation and complete randomisation. Nevertheless, the response-
adaptive designs targeting DA-optimal allocation and NP allocation led to a lower
total expected hazard, which means that they are more ethical compared with the
CR design.
The solution to NP is derived using the Lagrange multiplier method generalised
to inequality constraints. Details of the calculations can be found in Tymofyeyev
et al. (2007). As shown above, the closed form for the solution assumes the order of
the unknown parameters as p1 = ... = ps > ps+1 ≥ ... ≥ pJ−g > pJ−g+1 = ... = pJ
for binary responses and θ1 = ... = θs > θs+1 ≥ ... ≥ θJ−g > θJ−g+1 = ... = θJ for
exponential survival responses. Then the solution can be obtained by the Lagrange
multiplier method for binary and survival responses, which involve one parameter.
However, for normal responses, there is also a nuisance parameter. A closed form
for the solution to NP for multi-armed normal trials is not yet available.
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3.2.2. Optimal response-adaptive randomisation procedures
The optimal response-adaptive randomisation procedures described in Section
2.1.2 have been generalised to multi-armed clinical trials. Hu and Zhang (2004)
studied the DBCD and Zhang (2016) developed the ERADE for multi-armed trials,
which aim to target the pre-specified optimal allocations such as the DA-optimal
allocation and the NP allocation described in Section 3.2.1. Similar to two-armed
trials, the optimal allocations usually depend on the unknown parameters. There-
fore, a learning phase is required until initial parameter estimates are available.
Here, permuted-block randomisation is applied to the first 10% of the N patients.
Permuted-block randomisation can guarantee that the sample sizes on each of the
treatments are equal. Moreover, it can prevent the case where some arms receive
no patients, which can occur in the complete randomisation design.
After obtaining initial parameter estimates, the optimal response-adaptive ran-
domisation procedures can be implemented. Suppose that m
(i)
j is the cumulative
sample size on treatment j after i patients, i = 1, ..., N . Let m
(i)
j /i and ρ̂
(i)
j be
the current and target allocation proportions for treatment j, j = 1, ..., J, based
on the treatment assignments and responses obtained so far. Then the alloca-
tion probability functions for the DBCD and the ERADE are given below, which
depend on the current and the optimal allocation proportions.
Doubly-adaptive biased coin design

























}γ if 0 < m(i)j /i < 1,
1−m(i)j /i if m
(i)
j /i = 0, 1,
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where γ ∈ [0,∞) is a tuning parameter that controls the degree of randomness.
The DBCD is the most deterministic when γ →∞, whereas the procedure is the
most random when γ = 0. The value γ = 2 is commonly used for a reasonable
trade-off between variability and power. When m
(i)
j /i > ρ̂
(i)
j , the probability that
the next patient will be assigned to arm j is decreased and vice versa. At an
extreme case such as m
(i)
j /i = 1, it is impossible that the next patient will be




ψ(x) = 1 +
√
(x2γ
′ − 1) ∨ 0
be a weight function. Here, a ∨ b = max(a, b). The probability that the next

























) if 0 < m(i)j /i < 1,
1−m(i)j /i if m
(i)
j /i = 0, 1.
(3.13)
Here, the tuning parameter γ
′
can be any positive number. Through personal
communication, the author suggests a value 2 ≤ γ′ ≤ 4 to achieve a high power
while allowing a reasonable degree of randomness. Notice that, for multi-treatment
trials, gj in (3.13) is a continuous function, whereas, for two-armed trials, the al-
location probability function in (2.8) is discrete.
The generalisation of the ERADE to multiple treatments has also been shown
to attain the Cramér-Rao lower bound for the variance of the allocation propor-
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tions (Zhang, 2016). In other words, use of the ERADE guarantees the least
variability in the randomisation compared to other response-adaptive designs.
The optimal response-adaptive randomisation procedures require the optimal allo-
cation proportions ρ1, ..., ρJ to be continuous and twice continuously differentiable.
The DA-optimal allocation satisfies these conditions. However, the closed form so-
lution for the NP allocation is discontinuous when the parameters are all equal.
As can be seen in (3.11) for binary responses, Q is discontinuous when p1 = pJ .
In practice, the parameter estimates are used to obtain the optimal allocation.
Problems can also occur when the denominator p1 − pJ in Q has a value close to
zero, that is, when the value of p̂1 − p̂J is extremely small. The issue of disconti-
nuity can be addressed by replacing the denominator in Q by p1 − pJ + 1, where
p1 > pJ . This ensures that p̂1 − p̂J + 1 is a positive value, since p̂1, p̂J ∈ (0, 1).
The same approach can be used in (3.12) for censored survival responses to avoid
the denominator in Q being zero.
3.3. Simulation studies
3.3.1. Three-armed normal trials
Consider J = 3 treatments and testing HG0 : µG = 0 versus HGa : µG 6= 0, where
µG = (µE1 − µC , µE2 − µC)T , E1 and E2 refer to two experimental treatments,
and C denotes the control. The global test statistic (3.2) is used. The adaptive
designs without dropping inferior treatments are investigated by simulation in
terms of the error probabilities, the expected number of patients (ENP), the allo-
cation proportions and the corresponding standard deviations. The nominal type
I error rate was set to 0.05. There are K = 3 group sequential analyses planned
at equally and unequally spaced information times. The O’Brien and Fleming
boundaries (18.36, 9.18, 6.12) obtained from Table 16.1 in Jennison and Turnbull
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(2000) were used as an approximation. The boundaries were derived based on
normal responses with equal allocation and equal increments in information. For
optimal response-adaptive randomisation, the tuning parameters γ = γ
′
= 2 were
set for the DBCD and the ERADE functions. DA-optimal allocation was used
as the targeted optimal allocation for multi-armed normal trials. Results for the
group sequential CR design and fixed-sample CR and response-adaptive designs
are also provided for comparison. For the fixed-sample designs, the critical value
is 5.99. The maximum number of patients, N , is computed to achieve around 80%
power for the group sequential CR design. The simulation results are based on
5,000 replicates.
Table 3.1.: Simulated type I error rate for three-armed normal trials using com-
plete randomisation and response-adaptive randomisation, µE1 =
µE2 = µC = 16, σE1 = σE2 = σC = 10, N = 138.
Procedure α̃ ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.038 137.8 (3.3) 0.334 (0.039) 0.333 (0.039) 0.334 (0.039)
DBCDDA 0.037 137.7 (3.4) 0.333 (0.025) 0.334 (0.025) 0.333 (0.025)
ERADEDA 0.038 137.7 (3.8) 0.333 (0.022) 0.334 (0.022) 0.333 (0.023)
Table 3.2.: Simulated power for three-armed normal trials using complete ran-
domisation and response-adaptive randomisation, µE1 = 20, µE2 =
16, µC = 13, σE1 = σE2 = σC = 10, N = 138.
Procedure power ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.790 123.6 (21.5) 0.334 (0.041) 0.333 (0.041) 0.334 (0.042)
DBCDDA 0.814 122.0 (22.3) 0.342 (0.026) 0.333 (0.027) 0.326 (0.029)
ERADEDA 0.819 121.5 (22.6) 0.342 (0.024) 0.332 (0.025) 0.326 (0.026)
The target DA−optimal allocation is (0.333 0.333 0.333), since the variances are equal.
Tables 3.1 and 3.2 consider the case where the variance of the responses is equal
across treatments. In this case, the DA-optimal rule is equal allocation. Under
HG0 , from Table 3.1, the results for the adaptive designs and the group sequential
CR design are similar. However, the CR design consistently has a higher variabil-
ity in the allocation proportions. Here, a conservative type I error rate is obtained
– 61 –
3. Adaptive designs for multi-armed trials without dropping of inferior arm(s)
for all of the designs. This may be due to the fact that the test statistic (3.2)
for the unequal variances case is applied, σ̂2j,k, j = 1, 2, 3, is used in (3.3) and the
sample size is small in this case. If σ2j is used instead of σ̂
2
j,k, α̃ becomes 0.046 for
CR and the ERADE, and 0.047 for the DBCD.
Under the alternative hypothesis, from Table 3.2, the average allocation propor-
tion for experimental treatment 1, ρ̃E1, using the adaptive designs is 0.342, which
is within one standard deviation of the target allocation proportion, as are ρ̃E2 and
ρ̃C . The adaptive designs have a lower variability in the allocation proportions
than the CR design. In addition, compared with the CR design, the power for the
adaptive designs is around 3% higher.
Table 3.3.: Simulated type I error rate for three-armed normal trials using com-
plete randomisation and response-adaptive randomisation, µE1 =
µE2 = µC = 1, σE1 = 4, σE2 = 2, σC = 1, N = 300.
Procedure α̃ ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.051 299.0 (10.3) 0.333 (0.026) 0.333 (0.025) 0.334 (0.026)
DBCDDA 0.053 298.9 (10.3) 0.453 (0.015) 0.355 (0.019) 0.192 (0.018)
ERADEDA 0.048 299.2 (9.0) 0.451 (0.011) 0.355 (0.016) 0.194 (0.017)
The target DA−optimal allocation is (0.454, 0.356, 0.191).
Table 3.4.: Simulated power for three-armed normal trials using complete ran-
domisation and response-adaptive randomisation, µE1 = 2, µE2 =
1.5, µC = 1, σE1 = 4, σE2 = 2, σC = 1, N = 300.
Procedure power ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.792 261.1 (51.7) 0.333 (0.028) 0.334 (0.028) 0.333 (0.028)
DBCDDA 0.807 259.2 (52.5) 0.453 (0.016) 0.356 (0.020) 0.192 (0.020)
ERADEDA 0.811 257.7 (53.1) 0.451 (0.013) 0.355 (0.018) 0.193 (0.019)
Tables 3.3 - 3.6 consider the unequal variances case. Table 3.4 considers the case
where treatment arms that have a greater variance in response also have a higher
mean response, whereas Table 3.6 considers the case where the orders of the means
and the variances are not the same. For instance, E1 has the smallest mean re-
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sponse, yet the highest variance.
As can be seen from Tables 3.3 - 3.6, the adaptive designs targeting DA-optimal
allocation assign more patients to the treatment arm that has the larger vari-
ance under both the null and the alternative hypotheses. Both the DBCD and
the ERADE target the DA-optimal allocation well, with a difference of less than
one standard deviation from the target allocation proportions. In addition, the
ERADE consistently has the lowest variability in the allocation proportions.
Table 3.5.: Simulated type I error rate for three-armed normal trials using com-
plete randomisation and response-adaptive randomisation, µE1 =
µE2 = µC = 1, σE1 = 4, σE2 = 2, σC = 1, N = 410.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure α̃ ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.053 408.3 (15.2) 0.333 (0.022) 0.333 (0.022) 0.333 (0.022)
DBCDDA 0.051 408.5 (14.6) 0.453 (0.012) 0.355 (0.015) 0.192 (0.016)
ERADEDA 0.047 408.7 (13.0) 0.452 (0.009) 0.355 (0.013) 0.193 (0.014)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure α̃ ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.043 409.1 (8.5) 0.333 (0.022) 0.334 (0.022) 0.333 (0.022)
DBCDDA 0.052 409.1 (8.3) 0.453 (0.012) 0.355 (0.016) 0.191 (0.016)
ERADEDA 0.045 409.2 (8.3) 0.452 (0.009) 0.355 (0.013) 0.193 (0.014)
Fixed-sample design
Procedure α̃ ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.050 410 (0) 0.334 (0.022) 0.333 (0.022) 0.333 (0.022)
DBCDDA 0.050 410 (0) 0.453 (0.012) 0.355 (0.016) 0.192 (0.016)
ERADEDA 0.050 410 (0) 0.452 (0.009) 0.355 (0.013) 0.193 (0.014)
The target DA−optimal allocation is (0.454, 0.356, 0.191).
Under the null hypothesis, from Tables 3.3 and 3.5, the type I error rate for all of
the designs are close to the nominal value. For the fixed-sample designs and the
group sequential designs with equally spaced information times, α̃ is within one
standard error of 0.05. For group sequential analysis with (t1, t2, t3)=(0.5, 0.8,
1), α̃ for the DBCD, the ERADE and the CR designs is within one, two and three
standard errors, respectively. Since the parameters are all equal under HG0 , the
ENP for all of the designs is similar.
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Table 3.6.: Simulated power for three-armed normal trials using complete ran-
domisation and response-adaptive randomisation, µE1 = 1, µE2 =
2, µC = 1.5, σE1 = 4, σE2 = 2, σC = 1, N = 410.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure power ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.798 356.7 (70.5) 0.332 (0.024) 0.334 (0.024) 0.334 (0.024)
DBCDDA 0.841 348.6 (72.8) 0.452 (0.014) 0.354 (0.017) 0.194 (0.017)
ERADEDA 0.839 350.6 (72.6) 0.450 (0.010) 0.354 (0.014) 0.196 (0.016)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure power ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.797 368.0 (48.4) 0.334 (0.023) 0.334 (0.023) 0.333 (0.023)
DBCDDA 0.841 361.6 (50.8) 0.452 (0.013) 0.354 (0.016) 0.194 (0.016)
ERADEDA 0.837 362.1 (50.6) 0.451 (0.010) 0.354 (0.014) 0.195 (0.015)
Fixed-sample design
Procedure power ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.792 410 (0) 0.334 (0.022) 0.333 (0.022) 0.333 (0.022)
DBCDDA 0.838 410 (0) 0.452 (0.012) 0.354 (0.015) 0.193 (0.015)
ERADEDA 0.841 410 (0) 0.451 (0.009) 0.354 (0.013) 0.195 (0.014)
The target DA−optimal allocation is (0.454, 0.356, 0.191).
Under the alternative hypothesis, from Tables 3.4 and 3.6, the ENP is about 13%
lower under group sequential analysis compared to a fixed-sample design. For ex-
ample, in Table 3.4, the maximum number of patients is 300. However, the ENP
is around 260, due to the fact that early termination is allowed. In addition, use
of the adaptive designs can reduce the ENP slightly, yet yield a higher power com-
pared with the group sequential CR design. For instance, for (t1, t2, t3)=(0.33,
0.67, 1) in Table 3.6, the DBCD design can increase the power by around 4% while
using eight fewer patients on average compared to the CR design.
3.3.2. Three-armed binary trials
Consider testing HG0 : pG = 0 versus HGa : pG 6= 0 with pG = (pE1 − pC , pE2 −
pC)
T using test statistic (3.5), where the ps are the success rates for the treat-
ments. Tables 3.7 - 3.9 compare the adaptive designs with the group sequential
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CR design in terms of the error probabilities, the expected number of patients
(ENP) and the expected number of failures (ENF) for different scenarios of the
success rates. For binary responses, the DA-optimal allocation and the optimal
allocation based on nonlinear programming (NP) were used as the target alloca-
tions for the response-adaptive designs. For the NP allocation, the user-specified
lower bound for the allocation proportions was set to be B = 0.25. There are
K = 3 group sequential tests planned at equally spaced information times. The
O’Brien and Fleming critical boundaries derived based on normal responses with
equal allocation were used as an approximation. The type I error rate and other
settings were the same as in Section 3.3.1.
Table 3.7.: Simulated type I error rate for three-armed binary trials using complete
randomisation and response-adaptive randomisation.
pE1 pE2 pC N Procedure α̃ ENP (s.d.) ENF (s.d.)
0.2 0.2 0.2 210 CR 0.050 209.0 (8.5) 167.4 (8.9)
DBCDDA 0.069 208.2 (11.3) 166.5 (10.7)
ERADEDA 0.061 208.6 (10.3) 166.9 (10.1)
DBCDNP 0.076 207.8 (12.2) 166.3 (11.2)
ERADENP 0.073 208.0 (11.7) 166.4 (10.9)
0.5 0.5 0.5 600 CR 0.053 597.7 (21.4) 298.9 (10.7)
DBCDDA 0.047 598.2 (18.7) 299.1 (9.4)
ERADEDA 0.051 597.5 (22.5) 298.8 (11.2)
DBCDNP 0.051 598.0 (20.3) 299.0 (10.2)
ERADENP 0.049 597.2 (23.6) 298.6 (11.8)
0.6 0.6 0.6 81 CR 0.062 80.4 (4.6) 32.1 (4.7)
DBCDDA 0.071 80.2 (5.0) 32.0 (4.9)
ERADEDA 0.072 80.3 (4.6) 32.1 (4.8)
DBCDNP 0.063 80.4 (4.5) 32.1 (4.8)
ERADENP 0.056 80.4 (4.7) 32.1 (4.8)
0.7 0.7 0.7 289 CR 0.053 287.4 (12.9) 86.0 (8.7)
DBCDDA 0.059 287.0 (16.1) 86.0 (9.2)
ERADEDA 0.059 287.4 (13.4) 86.1 (8.7)
DBCDNP 0.048 287.9 (10.9) 86.1 (8.5)
ERADENP 0.047 287.9 (11.2) 86.3 (8.5)
Table 3.7 shows that the ENP is close to the maximum number of patients, N , and
that the ENF is close to qN under the null hypothesis where the parameters are
all equal, where q is the probability of failure. The type I error rate is close to the
nominal value for large sample sizes and when the success probabilities are close
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to 0.5. For pE1 = pE2 = pC = 0.5 and N = 600, α̃ is within one standard error of
0.05. For pE1 = pE2 = pC = 0.7 and N = 289, α̃ for CR and the response-adaptive
designs targeting the NP allocation is within one standard error, whereas, for the
DA-optimal designs, α̃ = 0.059 is three standard errors away. However, for small
sample sizes or when the success rates are close to zero or one, α̃ for the adaptive
designs can be inflated by around 1-2%, as shown in the first and third scenarios.
For pE1 = pE2 = pC = 0.6 and N = 81, α̃ for CR is also inflated to 0.062, which
is more than three standard errors above 0.05.
Table 3.8.: Simulated power for three-armed binary trials using complete randomi-
sation and response-adaptive randomisation.
pE1 pE2 pC N Procedure Power ENP (s.d.) ENF (s.d.)
0.3 0.2 0.1 210 CR 0.783 183.9 (35.9) 147.2 (30.0)
DBCDDA 0.795 180.8 (36.4) 143.0 (30.5)
ERADEDA 0.785 181.9 (36.3) 143.9 (30.4)
DBCDNP 0.784 180.8 (36.5) 140.0 (30.0)
ERADENP 0.783 181.3 (36.3) 140.3 (29.9)
0.65 0.55 0.5 600 CR 0.805 518.1 (104.3) 224.5 (45.2)
DBCDDA 0.800 517.5 (103.9) 224.7 (45.0)
ERADEDA 0.806 517.2 (105.6) 224.5 (45.7)
DBCDNP 0.829 513.5 (105.7) 214.1 (44.0)
ERADENP 0.823 511.8 (106.0) 213.6 (44.2)
0.8 0.6 0.4 81 CR 0.790 68.7 (15.7) 27.4 (7.2)
DBCDDA 0.810 67.6 (16.0) 27.6 (7.0)
ERADEDA 0.805 68.0 (15.8) 27.8 (6.9)
DBCDNP 0.823 66.7 (16.8) 25.5 (6.6)
ERADENP 0.819 67.2 (16.5) 25.7 (6.5)
0.8 0.7 0.6 289 CR 0.795 249.3 (51.3) 74.9 (16.6)
DBCDDA 0.803 246.7 (54.2) 75.1 (17.5)
ERADEDA 0.801 247.1 (54.4) 75.3 (17.4)
DBCDNP 0.800 247.8 (52.8) 71.2 (15.7)
ERADENP 0.796 248.0 (52.3) 71.4 (15.6)
Under the alternative hypothesis, from Table 3.8, since the type I error rate is
not comparable for the designs in the first and third scenarios, the power can not
be compared directly. The increase in the power for the adaptive designs may be
because of the inflation in the type I error rate. Looking at the second scenario
with a large sample size, it is clear that the power for CR and the adaptive designs
using the DA-optimal allocation is similar at about 80%. This is because, for a
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small difference in the variances of the responses for the treatments, DA-optimal
allocation is close to equal allocation. However, for the NP allocation, the power is
increased to around 82% while using fewer patients on average even in such a case
where the treatment contrasts are quite small. Moreover, the adaptive designs
using the NP allocation can also reduce the ENF by about 11 compared with the
other designs.
Table 3.9.: Simulated allocation proportions for three-armed binary trials using
complete randomisation and response-adaptive randomisation.
pE1 pE2 pC N Procedure ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.) ρE1 ρE2 ρC
0.3 0.2 0.1 210 CR 0.333 (0.033) 0.333 (0.033) 0.334 (0.033) 0.333 0.333 0.333
DBCDDA 0.376 (0.026) 0.347 (0.031) 0.277 (0.040) 0.374 0.346 0.280
ERADEDA 0.375 (0.023) 0.347 (0.029) 0.278 (0.037) 0.374 0.346 0.280
DBCDNP 0.496 (0.085) 0.281 (0.081) 0.223 (0.029) 0.520 0.250 0.230
ERADENP 0.491 (0.086) 0.285 (0.082) 0.224 (0.030) 0.520 0.250 0.230
0.65 0.55 0.5 600 CR 0.333 (0.020) 0.333 (0.020) 0.333 (0.020) 0.333 0.333 0.333
DBCDDA 0.326 (0.011) 0.336 (0.010) 0.338 (0.010) 0.327 0.336 0.337
ERADEDA 0.326 (0.008) 0.336 (0.007) 0.337 (0.007) 0.327 0.336 0.337
DBCDNP 0.464 (0.035) 0.266 (0.035) 0.270 (0.017) 0.479 0.250 0.271
ERADENP 0.461 (0.039) 0.269 (0.040) 0.270 (0.018) 0.479 0.250 0.271
0.8 0.6 0.4 81 CR 0.335 (0.054) 0.332 (0.054) 0.333 (0.054) 0.333 0.333 0.333
DBCDDA 0.302 (0.042) 0.349 (0.035) 0.349 (0.036) 0.303 0.349 0.349
ERADEDA 0.303 (0.040) 0.349 (0.032) 0.348 (0.032) 0.303 0.349 0.349
DBCDNP 0.395 (0.060) 0.281 (0.053) 0.324 (0.052) 0.420 0.250 0.330
ERADENP 0.395 (0.058) 0.282 (0.054) 0.322 (0.051) 0.420 0.250 0.330
0.8 0.7 0.6 289 CR 0.333 (0.029) 0.334 (0.029) 0.333 (0.029) 0.333 0.333 0.333
DBCDDA 0.305 (0.027) 0.340 (0.021) 0.355 (0.019) 0.308 0.339 0.353
ERADEDA 0.305 (0.025) 0.340 (0.019) 0.355 (0.016) 0.308 0.339 0.353
DBCDNP 0.420 (0.050) 0.279 (0.050) 0.301 (0.034) 0.446 0.250 0.304
ERADENP 0.418 (0.050) 0.281 (0.052) 0.300 (0.034) 0.446 0.250 0.304
As shown in Table 3.9, the adaptive designs using theDA-optimal rule perform well
in terms of targeting the optimal allocation for both the accuracy and efficiency.
For the NP allocation, treatment assignment using the closed form solution (3.11)
is based on the order of the current parameter estimates. When the sample size is
small early in the trials, the parameter estimates are less accurate. The order of
the parameter estimates can also be inconsistent with respect to the true values.
Hence, the variability in the allocation proportions for the NP allocation seems
to be higher than for the other designs. These findings support the theory that
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the DA-optimal rule ensures the most efficient estimates, while the NP allocation
maximises the power of the test of homogeneity subject to a fixed total number
of patients.
Focusing on the second scenario with a large sample size, Tables 3.10 and 3.11
compare the designs under group sequential monitoring with equal and unequal
increments in information time. Also, fixed-sample designs are provided alongside.
Under the null hypothesis in Table 3.10, the type I error rate can be well preserved
for the case when (t1, t2, t3) = (0.5, 0.8, 1), where α̃ is within two standard errors
of the nominal value. This indicates that the sequential critical boundaries can
also be applied as an approximate result to the case of unequally-spaced informa-
tion times for large sample sizes.
Table 3.10.: Simulated type I error rate for three-armed binary trials using com-
plete randomisation and response-adaptive randomisation, pE1 =
pE2 = pC = 0.5, N = 600.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.053 597.7 (21.4) 298.9 (10.7) 0.333 (0.018) 0.333 (0.018) 0.333 (0.018)
DBCDDA 0.047 598.2 (18.7) 299.1 (9.4) 0.333 (0.009) 0.333 (0.009) 0.333 (0.009)
ERADEDA 0.051 597.5 (22.5) 298.8 (11.2) 0.333 (0.006) 0.333 (0.006) 0.333 (0.006)
DBCDNP 0.051 598.0 (20.3) 299.0 (10.2) 0.332 (0.093) 0.334 (0.094) 0.334 (0.094)
ERADENP 0.049 597.2 (23.6) 298.6 (11.8) 0.331 (0.094) 0.336 (0.095) 0.333 (0.094)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.050 598.9 (11.2) 299.5 (5.6) 0.333 (0.018) 0.333 (0.018) 0.333 (0.018)
DBCDDA 0.050 598.7 (12.4) 299.4 (6.2) 0.333 (0.009) 0.333 (0.009) 0.333 (0.009)
ERADEDA 0.049 598.6 (13.8) 299.3 (6.9) 0.333 (0.006) 0.333 (0.006) 0.333 (0.006)
DBCDNP 0.048 598.5 (13.7) 299.3 (6.9) 0.333 (0.093) 0.335 (0.093) 0.332 (0.092)
ERADENP 0.044 598.7 (12.3) 299.4 (6.1) 0.333 (0.095) 0.331 (0.094) 0.336 (0.095)
Fixed-sample design
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.051 600 (0) 300 (0) 0.333 (0.018) 0.333 (0.018) 0.333 (0.018)
DBCDDA 0.052 600 (0) 300 (0) 0.333 (0.009) 0.333 (0.009) 0.333 (0.009)
ERADEDA 0.052 600 (0) 300 (0) 0.333 (0.006) 0.333 (0.006) 0.333 (0.006)
DBCDNP 0.047 600 (0) 300 (0) 0.332 (0.093) 0.333 (0.094) 0.336 (0.094)
ERADENP 0.045 600 (0) 300 (0) 0.332 (0.095) 0.333 (0.095) 0.335 (0.096)
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Table 3.11.: Simulated power for three-armed binary trials using complete ran-
domisation and response-adaptive randomisation, pE1 = 0.65, pE2 =
0.55, pC = 0.5, N = 600.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure Power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.805 518.1 (104.3) 244.5 (45.2) 253.4 (9.6) 0.333 (0.020) 0.333 (0.020) 0.333 (0.020)
DBCDDA 0.800 517.5 (103.9) 224.7 (45.0) 253.7 (9.5) 0.326 (0.011) 0.336 (0.010) 0.338 (0.010)
ERADEDA 0.806 517.2 (105.6) 224.5 (45.7) 253.7 (9.6) 0.326 (0.008) 0.336 (0.007) 0.337 (0.007)
DBCDNP 0.829 513.5 (105.7) 214.1 (44.0) 244.5 (7.4) 0.464 (0.035) 0.266 (0.035) 0.270 (0.017)
ERADENP 0.823 511.8 (106.0) 213.6 (44.2) 244.6 (7.7) 0.461 (0.039) 0.269 (0.040) 0.270 (0.018)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure Power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.809 536.0 (74.4) 232.2 (32.3) 254.8 (7.4) 0.333 (0.019) 0.333 (0.019) 0.333 (0.019)
DBCDDA 0.809 535.7 (74.3) 232.6 (32.1) 255.2 (7.2) 0.326 (0.010) 0.336 (0.010) 0.337 (0.009)
ERADEDA 0.813 534.8 (74.2) 232.2 (32.1) 255.1 (7.2) 0.326 (0.008) 0.336 (0.007) 0.337 (0.006)
DBCDNP 0.832 529.8 (75.5) 220.9 (31.5) 245.6 (5.6) 0.465 (0.035) 0.266 (0.035) 0.270 (0.017)
ERADENP 0.814 530.6 (76.4) 221.3 (31.9) 245.7 (5.7) 0.463 (0.037) 0.267 (0.038) 0.270 (0.018)
Fixed-sample design
Procedure Power ENP (s.d.) ENF (s.d.) - - ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.812 600 (0) 260.0 (1.4) - - 0.333 (0.018) 0.333 (0.018) 0.333 (0.018)
DBCDDA 0.813 600 (0) 260.5 (0.7) - - 0.327 (0.009) 0.336 (0.009) 0.337 (0.009)
ERADEDA 0.813 600 (0) 260.5 (0.5) - - 0.327 (0.007) 0.336 (0.006) 0.337 (0.006)
DBCDNP 0.833 600 (0) 250.2 (2.3) - - 0.465 (0.036) 0.265 (0.036) 0.270 (0.017)
ERADENP 0.828 600 (0) 250.2 (2.3) - - 0.464 (0.035) 0.266 (0.036) 0.270 (0.017)
The target DA-optimal and NP allocations are (0.327, 0.336, 0.337) and (0.479, 0.25,
0.271), respectively.
Under the alternative hypothesis, in Table 3.11, the ENP and hence the ENF are
lower for the group sequential designs than for the fixed-sample designs. To see
the advantages of using response-adaptive designs over CR using the same number
of subjects, the ENF is calculated based on the maximum number of patients.
When trials stop at an interim analysis, the rest of the patients are assigned to
the better-performing treatment and the expected number of failures for the rest
of the patients is (1 − p1)E(Nrest), where p1 is the probability of success for the
best-performing treatment and Nrest denotes the number of remaining patients.
Based on the same sample size, the ENF
′
for the group sequential designs can be
used to compare with the ENF for the fixed-sample designs. In practice, trials
stop when a decision is made.
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3.3.3. Three-armed censored survival trials
Consider testing HG0 : θG = 0 versus HGa : θG 6= 0 with θG = (θE1 − θC , θE2 −
θC)
T using test statistic (3.7), where θj refers to the mean survival time for treat-
ment j. This testing problem has been investigated by Sverdlov et al. (2011) using
a fixed-sample design with the DBCD, and their simulation settings were based
on the head and neck cancer experiment (Fountzilas et al., 2004). Here, similar
simulation settings are considered. The duration of the trial D is 96 months.
Independent exponentially distributed survival times and uniformly distributed
arrival and censoring times are assumed. The DA-optimal allocation and the op-
timal allocation based on nonlinear programming (NP) were used as the target
allocations for the optimal response-adaptive designs. For the NP allocation, the
user-specified lower bound for the allocation proportions B was set to be 0.20
to satisfy B ∈ [0, B̃], B̃ = min(B̃1, B̃3, 1/3), in (3.12). There are K = 3 group
sequential tests at equally spaced information times. The type I error rate, the
approximate critical boundaries and other settings are the same as in Section 3.3.1.
From Table 3.12, we find that the critical boundaries derived based on normal
responses can be used as an approximation here. The type I error rate for all of
the designs is less than 0.01 from 0.05. The differences in the ENP and the ENF
among the designs are small under HG0 .
Table 3.12.: Simulated type I error rate for three-armed censored survival trials
using complete randomisation and response-adaptive randomisation,
θE1 = θE2 = θC = 24, N = 312.
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.041 311.4 (7.0) 193.9 (4.4) 0.333 (0.025) 0.333 (0.025) 0.333 (0.025)
DBCDDA 0.058 310.3 (12.3) 193.2 (7.7) 0.333 (0.034) 0.333 (0.034) 0.333 (0.034)
ERADEDA 0.057 310.7 (10.7) 193.5 (6.6) 0.333 (0.031) 0.334 (0.031) 0.333 (0.030)
DBCDNP 0.058 310.5 (10.8) 193.4 (6.7) 0.336 (0.091) 0.332 (0.090) 0.332 (0.090)
ERADENP 0.052 310.9 (10.0) 193.6 (6.2) 0.333 (0.088) 0.334 (0.089) 0.332 (0.089)
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Under the alternative hypothesis, from Table 3.13, the response-adaptive designs
using the NP allocation can achieve a higher power and reduce the ENP and the
ENF compared with the other designs. For instance, the use of the NP allocation
can increase the power by around 4 % compared to the DA-optimal allocation.
Meanwhile, about seven fewer patients on average were used and nine events are
prevented. However, compared with the NP allocation, the DA-optimal rule has
more accuracy and precision in targeting the optimal allocation proportions.
Table 3.13.: Simulated power for three-armed censored survival trials using com-
plete randomisation and response-adaptive randomisation, θE1 =
34, θE2 = 24, θC = 20, N = 312.
Procedure power ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.733 294.7 (32.9) 178.8 (20.1) 0.334 (0.026) 0.333 (0.026) 0.333 (0.026)
DBCDDA 0.785 284.9 (38.9) 170.0 (23.8) 0.409 (0.029) 0.324 (0.039) 0.268 (0.041)
ERADEDA 0.788 284.8 (38.8) 170.0 (23.7) 0.407 (0.026) 0.325 (0.035) 0.269 (0.037)
DBCDNP 0.827 277.2 (40.5) 161.8 (25.0) 0.533 (0.092) 0.229 (0.062) 0.238 (0.050)
ERADENP 0.824 278.0 (40.4) 162.5 (24.9) 0.526 (0.091) 0.234 (0.065) 0.240 (0.048)
The target DA-optimal and NP allocations are (0.406, 0.323, 0.271) and (0.544, 0.2,
0.256), respectively.
Tables 3.14 and 3.15 compare the designs under group sequential monitoring with
equal and unequal increments in information time. The fixed-sample designs are
provided alongside for comparison. The maximum number of patients, N , is com-
puted by simulation to attain around 80% power for the group sequential CR
design. Compared with the settings in Tables 3.12 and 3.13, the mean survival
time for each treatment is increased. When the mean survival time is 24 months
as in Table 3.12, the probability of an event computed by (2.11) is 0.62, whereas,
when the mean survival time is 45 months, as in Table 3.14, the probability is
0.45. Thus, the chance of observing a non-censored event is high when survival
is poor. Therefore, the probability of a censored response is increased for longer
mean survival times. In other words, more patients would not have responded by
the end of the study.
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Tables 3.14 and 3.15 demonstrate similar behaviour as Tables 3.12 and 3.13. In
brief, the adaptive designs with the NP optimal allocation can achieve a higher
power and reduce the ENP and the ENF, whereas, those using the DA-optimal
allocation have lower variation in the allocation proportions compared with the
NP optimal allocation. In addition, the critical boundaries can be used as an
approximation to preserve the type I error rate for multi-armed censored survival
trials with equal and unequal increments in information time.
Table 3.14.: Simulated type I error rate for three-armed censored survival trials
using complete randomisation and response-adaptive randomisation,
θE1 = θE2 = θC = 45, N = 600.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.040 599.2 (10.5) 269.6 (4.7) 0.334 (0.018) 0.333 (0.018) 0.333 (0.018)
DBCDDA 0.048 598.4 (14.6) 269.2 (6.6) 0.334 (0.029) 0.333 (0.030) 0.333 (0.029)
ERADEDA 0.050 598.5 (14.5) 269.3 (6.5) 0.333 (0.026) 0.333 (0.026) 0.333 (0.026)
DBCDNP 0.045 598.4 (14.7) 269.2 (6.6) 0.331 (0.084) 0.334 (0.084) 0.335 (0.085)
ERADENP 0.048 598.5 (13.8) 269.3 (6.2) 0.332 (0.081) 0.336 (0.081) 0.332 (0.081)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.039 599.5 (6.2) 269.7 (2.8) 0.334 (0.018) 0.333 (0.018) 0.333 (0.018)
DBCDDA 0.049 598.8 (11.0) 269.4 (5.0) 0.333 (0.029) 0.333 (0.030) 0.333 (0.029)
ERADEDA 0.051 599.0 (9.4) 269.5 (4.2) 0.333 (0.027) 0.334 (0.027) 0.333 (0.026)
DBCDNP 0.048 598.9 (9.9) 269.4 (4.4) 0.336 (0.085) 0.333 (0.084) 0.332 (0.082)
ERADENP 0.044 599.1 (8.3) 269.6 (3.7) 0.335 (0.083) 0.331 (0.081) 0.334 (0.083)
Fixed-sample design
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.041 600 (0) 269.9 (0.0) 0.334 (0.018) 0.333 (0.018) 0.333 (0.018)
DBCDDA 0.051 600 (0) 269.9 (0.0) 0.334 (0.029) 0.333 (0.029) 0.333 (0.029)
ERADEDA 0.050 600 (0) 269.9 (0.0) 0.334 (0.026) 0.333 (0.027) 0.333 (0.027)
DBCDNP 0.048 600 (0) 269.9 (1.8) 0.332 (0.088) 0.333 (0.087) 0.334 (0.088)
ERADENP 0.042 600 (0) 269.9 (0.0) 0.332 (0.086) 0.334 (0.085) 0.334 (0.087)
It is worth mentioning that theDA-optimal allocation is always ethical for censored
survival responses. More specifically, the DA-optimal rule assigns more patients
to the treatment with a higher variance in the responses, which corresponds to
the treatment with the higher mean survival time. Sverdlov et al. (2011) proved
in theory that, if θ1 ≥ ... ≥ θJ , then ρ1 ≥ ... ≥ ρJ for the DA-optimal allocation.
The results displayed in Tables 3.13 and 3.15 support the theory. However, the
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property does not hold for normal and binary responses, where the most efficient
allocation may assign more patients to the less promising treatments.
Table 3.15.: Simulated power for three-armed censored survival trials using com-
plete randomisation and response-adaptive randomisation, θE1 =
59, θE2 = 45, θC = 37, N = 600.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure Power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.807 556.3 (62.1) 247.0 (27.7) 263.6 (4.3) 0.334 (0.019) 0.333 (0.019) 0.333 (0.019)
DBCDDA 0.829 545.4 (66.2) 237.7 (29.9) 258.5 (5.0) 0.401 (0.027) 0.331 (0.033) 0.269 (0.035)
ERADEDA 0.835 547.0 (65.9) 238.4 (29.8) 258.6 (5.0) 0.400 (0.023) 0.331 (0.030) 0.269 (0.033)
DBCDNP 0.853 536.8 (67.6) 229.6 (31.1) 253.6 (7.0) 0.506 (0.093) 0.239 (0.066) 0.254 (0.048)
ERADENP 0.844 537.9 (66.9) 230.4 (30.8) 254.0 (7.0) 0.499 (0.095) 0.243 (0.070) 0.257 (0.048)
(t1, t2, t3)=(0.5, 0.8, 1)
Procedure Power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.791 566.4 (40.5) 251.4 (18.1) 264.2 (3.0) 0.334 (0.019) 0.333 (0.019) 0.333 (0.019)
DBCDDA 0.822 558.2 (45.1) 243.2 (20.9) 259.1 (4.0) 0.401 (0.026) 0.331 (0.032) 0.268 (0.034)
ERADEDA 0.818 558.6 (45.1) 243.5 (20.8) 259.2 (3.9) 0.399 (0.023) 0.331 (0.029) 0.270 (0.031)
DBCDNP 0.846 552.2 (46.1) 236.1 (22.2) 254.3 (6.3) 0.507 (0.093) 0.236 (0.064) 0.257 (0.048)
ERADENP 0.842 552.2 (45.9) 236.5 (22.3) 254.6 (6.5) 0.500 (0.096) 0.240 (0.068) 0.259 (0.048)
Fixed-sample design
Procedure Power ENP (s.d.) ENF (s.d.) - - ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.763 600 (0) 266.3 (1.2) - - 0.334 (0.018) 0.333 (0.018) 0.333 (0.018)
DBCDDA 0.804 600 (0) 261.5 (1.7) - - 0.399 (0.024) 0.331 (0.029) 0.270 (0.030)
ERADEDA 0.797 600 (0) 261.5 (1.6) - - 0.398 (0.022) 0.330 (0.027) 0.272 (0.028)
DBCDNP 0.835 600 (0) 256.4 (5.4) - - 0.510 (0.092) 0.230 (0.062) 0.261 (0.051)
ERADENP 0.831 600 (0) 256.6 (5.3) - - 0.506 (0.091) 0.231 (0.061) 0.263 (0.050)
The target DA-optimal and NP allocations are (0.400, 0.330, 0.270) and (0.519, 0.2,
0.281), respectively.
3.3.4. Redesigning a four-armed binary trial
In the previous sections, three-treatment comparisons were considered. The adap-
tive designs can also be applied to multi-armed clinical trials with J > 3 treat-
ments. In this section, a four-armed binary trial is redesigned. NeoSphere (Gianni
et al., 2012) is a phase II randomised clinical trial which compares the efficacy and
safety of different combinations of treatments for women with breast cancer. An-
tibody trastuzumab with concomitant chemotherapy docetaxel is a conventional
treatment for the cancer. The NeoSphere trial examined the activity of another
anibody, pertuzumab, by assessing the effects of pertuzumab combined with ei-
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ther trastuzumab, docetaxel or both. The trial consisted of trastuzumab plus do-
cetaxel (control), pertuzumab and trastuzumab plus docetaxel (E1), pertuzumab
and trastuzumab (E2), and pertuzumab plus docetaxel (E3).
There were 417 eligible women randomly assigned to the treatment groups with
equal probabilities. The numbers of patients in the control group and on the ex-
perimental treatment arms E1 and E2 were 107, and 96 patients were assigned to
E3 since this was added to the study after a protocol amendment. The endpoint
considered in the study was pathological complete response, which is dichotomised
and serves as a surrogate for long-term efficacy. The complete response rate was
29% for the control, 45.8% for E1, 16.8% for E2 and 24% for E3. The study
concluded that E1 had a significantly higher complete response rate compared to
the conventional control group.
Here, the trial is redesigned using the adaptive designs without dropping inferior
treatments. Let pC = 0.29, pE1 = 0.458, pE2 = 0.168 and pE3 = 0.24. The global
null hypothesis HG0 : pG = 0 versus the alternative hypothesis HGa : pG 6= 0 with
pG = (pE1−pC , pE2−pC , pE3−pC)T is tested. For the combined approach, the first
40 patients were randomly assigned using permuted-block randomisation with ra-
tio 1:1:1:1 to obtain initial parameter estimates. Then optimal response-adaptive
randomisation using the DA-optimal allocation and the optimal allocation based
on nonlinear programming (NP) was performed.
For the NP allocation, the user-specified lower bound for the allocation propor-
tions B was set to be 0.20 to satisfy B ∈ [0, B̃], where B̃ = min(B̃1, B̃4, 1/4) in
(3.11). The closed form solution for NP optimal allocation requires the order of
the parameters to be p1 > p2 ≥ p3 > p4. Let p1 = pE1, p2 = pC , p3 = pE3 and
p4 = pE2. Then the optimal allocation proportions based on nonlinear program-
ming which maximise the power subject to the total sample size not exceeding a
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fixed value are
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When B = 0, the solution maximises the power but reduces to Neyman allocation
for J = 2, where patients are assigned to the best and the worst treatments only.
When B = 1/4, the solution becomes equal allocation.
For the DA-optimal allocation, the target allocation proportions for the four-
treatment trial can be obtained by solving the system of equations in (3.9), where
J − 1 = 3.
The nominal type I error rate was set to 5% and K = 3 group sequential tests were
planned at equally spaced information times. The O’Brien and Fleming critical
boundaries (23.76, 11.88, 7.92) for J = 4 treatments obtained from Table 16.1 in
Jennison and Turnbull (2000) were used as an approximation. The boundaries
were derived based on normal responses with equal variances. Results for the
group sequential CR design and the fixed-sample CR and response-adaptive de-
signs are also provided for comparison. For the fixed-sample designs, the critical
boundary is 7.81. The simulation results are based on 5,000 replicates.
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Under the null hypothesis, from Table 3.16, the type I error rate for the fixed-
sample designs is well controlled in general. However, for the combined approach
using the DBCD, α̃ is inflated. For the ERADE designs, α̃ lies within three
standard errors of 0.05. This may be due to the fact that critical boundaries
derived based on normal responses and equal variances with equal allocation are
used as an approximation here. Under the null hypothesis where the parameters
are all equal, the probability of early termination is small. The differences in the
ENP and the ENF for the group sequential and fixed-sample designs are small.
In addition, under HG0 , the optimal allocation proportions are close to equal
allocation, with the DA-optimal allocation consistently having the least variation
in the allocation proportions.
Table 3.16.: Simulated type I error rate for redesigning NeoSphere trial using
complete randomisation and response-adaptive randomisation, pC =
0.29, pE1 = 0.29, pE2 = 0.29, pE3 = 0.29, N = 417.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃C (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃E3 (s.d.)
CR 0.050 415.7 (13.9) 295.1 (9.9) 0.250 (0.020) 0.250 (0.020) 0.250 (0.020) 0.250 (0.020)
DBCDDA 0.061 414.7 (20.9) 294.4 (14.8) 0.250 (0.012) 0.250 (0.012) 0.250 (0.012) 0.250 (0.011)
ERADEDA 0.058 414.9 (17.5) 294.6 (12.4) 0.250 (0.009) 0.250 (0.009) 0.250 (0.009) 0.250 (0.009)
DBCDNP 0.069 413.6 (25.1) 293.6 (17.8) 0.244 (0.108) 0.244 (0.116) 0.243 (0.115) 0.268 (0.105)
ERADENP 0.057 414.3 (21.4) 294.2 (15.2) 0.243 (0.108) 0.246 (0.115) 0.245 (0.114) 0.267 (0.105)
Fixed-sample design
Procedure α̃ ENP (s.d.) ENF (s.d.) ρ̃C (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃E3 (s.d.)
CR 0.054 417 (0) 296.1 (0) 0.250 (0.020) 0.250 (0.020) 0.250 (0.020) 0.250 (0.020)
DBCDDA 0.056 417 (0) 296.1 (0) 0.250 (0.011) 0.250 (0.011) 0.250 (0.011) 0.250 (0.011)
ERADEDA 0.058 417 (0) 296.1 (0) 0.250 (0.009) 0.250 (0.009) 0.250 (0.009) 0.250 (0.009)
DBCDNP 0.055 417 (0) 296.1 (0) 0.242 (0.108) 0.245 (0.117) 0.246 (0.116) 0.266 (0.104)
ERADENP 0.055 417 (0) 296.1 (0) 0.241 (0.107) 0.246 (0.115) 0.245 (0.115) 0.268 (0.105)
Since there are significant differences in the treatment effects, a high probability
of rejecting HG0 under the alternative hypothesis is obtained for all of the designs:
see Table 3.17. This agrees with the finding of Gianni et al. (2012) that patients
who received pertuzumab and trastuzumab plus docetaxel (E1) had a significantly
improved pathological complete response rate compared to those who received the
control, where a two-sided Mantel-Haenszel test was used.
The total number of failures in the NeoSphere trial was 296 (Gianni et al., 2012).
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A similar figure for the expected number of failures (ENF), 296.5, is found for the
fixed-sample CR design. If fixed-sample response-adaptive designs are used, about
two fewer failures on average would be avoided using the DA-optimal allocation
and around 22 fewer could be achieved using the NP allocation. In addition, if
group-sequential response-adaptive designs are used, a further reduction in the
ENF could be obtained. Since the expected number of patients (ENP) for the
group sequential designs is substantially lower than the fixed-sample designs, the
ENF is also decreased. If the group-sequential response-adaptive design with DA-
optimal allocation is applied, around 86 failures could be avoided. If the NP
allocation is used, about 109 fewer failures can be achieved.
Table 3.17.: Simulated power for redesigning NeoSphere trial using complete ran-
domisation and response-adaptive randomisation, pC = 0.29, pE1 =
0.458, pE2 = 0.168, pE3 = 0.24, N = 417.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure power ENP (s.d.) ENF (s.d.) ENF
′
(s.d.) ρ̃C (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃E3 (s.d.)
CR 0.987 304.5 (70.3) 216.5 (50.1) 277.9 (12.2) 0.249 (0.024) 0.250 (0.024) 0.251 (0.024) 0.250 (0.024)
DBCDDA 0.991 298.8 (72.5) 210.9 (51.5) 275.3 (12.4) 0.256 (0.015) 0.267 (0.013) 0.229 (0.021) 0.248 (0.017)
ERADEDA 0.987 297.3 (72.6) 209.8 (51.6) 275.1 (12.4) 0.256 (0.014) 0.267 (0.011) 0.229 (0.020) 0.248 (0.015)
DBCDNP 0.994 284.0 (71.5) 187.3 (47.2) 259.5 (8.9) 0.198 (0.037) 0.465 (0.038) 0.152 (0.031) 0.185 (0.032)
ERADENP 0.993 282.0 (72.4) 186.4 (48.0) 259.7 (9.2) 0.199 (0.038) 0.460 (0.040) 0.154 (0.029) 0.187 (0.031)
Fixed-sample design
Procedure power ENP (s.d.) ENF (s.d.) - - ρ̃C (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃E3 (s.d.)
CR 0.989 417 (0) 296.5 (2.1) - - 0.250 (0.020) 0.250 (0.020) 0.250 (0.020) 0.250 (0.020)
DBCDDA 0.990 417 (0) 294.3 (1.3) - - 0.256 (0.012) 0.267 (0.011) 0.230 (0.015) 0.248 (0.012)
ERADEDA 0.989 417 (0) 294.3 (1.0) - - 0.256 (0.009) 0.266 (0.008) 0.230 (0.013) 0.248 (0.010)
DBCDNP 0.994 417 (0) 274.4 (2.8) - - 0.198 (0.030) 0.470 (0.033) 0.145 (0.029) 0.187 (0.030)
ERADENP 0.995 417 (0) 274.7 (2.6) - - 0.198 (0.028) 0.468 (0.030) 0.147 (0.027) 0.188 (0.027)
The target DA-optimal and NP allocations are (0.256, 0.266, 0.230, 0.248) and (0.2,
0.479, 0.121, 0.2), respectively.
The ENF
′
for the group sequential designs is calculated based on N = 417 patients
to compare with the fixed-sample designs. In practice, trials stop when a decision
is made. The ENF
′
is also consistently lower than the ENF for the fixed-sample
designs, since the rest of the patients are assigned to the most promising treatment
if trials stop early. For instance, for the NP allocation, the ENF
′
for the group
sequential designs is about 15 less than the ENF for the fixed-sample designs. The
other designs achieve around 20 fewer failures.
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3.4. Conclusions
Based on the results obtained in this chapter, the critical boundaries derived
based on normal responses with equal allocation and equally spaced information
times (Jennison and Turnbull, 1991, 2000) can be used as an approximation for
the adaptive design with equal and unequally spaced information times for multi-
armed normal trials. For trials with binary and censored survival responses, the
overall type I error rate can also be controlled when the sample size is large.
Compared with the group sequential CR design, the adaptive designs can increase
the power of the tests of homogeneity while decreasing the average numbers of pa-
tients and failures. Both optimal response-adaptive designs can target the specified
optimal allocations well, with the ERADE consistently having a lower variability
in the allocation proportions than the DBCD. Comparing the two optimal alloca-
tions derived based on different optimality criteria, in general, the adaptive designs
with the DA-optimal allocation have a lower variance for the allocation propor-
tions, whereas the NP allocation can achieve a higher power while minimising the
average number of patients.
For the NP allocation, more patients are assigned to the best and the worst treat-
ments, while the allocation proportions for the other treatment(s) are fixed. Such
allocation is according to the order of the current parameter estimates. The closed
form solution for NP allocation is available for binary and survival responses with
one parameter. However, for normal responses, which involve a nuisance parame-
ter, a solution has not yet been derived. Here, the NP allocation that maximises
the power subject to the total sample size not exceeding a fixed value is considered.
For NP allocation which maximises the power subject to a fixed total number of
failures, there is no closed form for the solution. Numerical methods are required.
The DA-optimal allocation, which depends on the variance of the responses for




multi-armed trials with dropping
of inferior arm(s)
4.1. Global and pairwise tests
As can be seen from the simulation results in Chapter 3, the combined approach
can be used for global tests of homogeneity. However, when the global null hy-
pothesis is rejected at an interim analysis, one probably does not want to end
the entire trial. Testing which treatments differ is usually of concern. The group
sequential Fisher’s least significant difference (LSD) method, which consists of a
global test and pairwise comparisons, has been studied (Proschan et al., 1994).
First, a global test statistic is monitored sequentially to test for the homogeneity
of treatment effects. If the global null hypothesis is rejected, unadjusted pairwise
comparisons are conducted at this and subsequent looks if the trial proceeds. Infe-
rior treatments can be dropped after pairwise comparisons. However, the authors
considered the cases of equal allocation and fixed unequal allocation determined
before the commencement of the experiments.
In this chapter, an analogue of Fisher’s LSD method that generalises to group-
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sequential response-adaptive designs is investigated. The test statistics described
in Chapters 2 and 3 can be used for the pairwise and global tests, respectively. For
simplicity, the design for three-armed normal trials is illustrated, which can be ap-
plied to other types of responses and extended to more than three treatment arms.
Let K be the number of group sequential analyses. First, we wish to test the global
null hypothesis HG0 : µG = 0 versus the alternative hypothesis HGa : µG 6= 0,
where µG = (µE1−µC , µE2−µC)T is a vector of treatment contrasts and C refers to
the control group. The test statistics Sk and the corresponding critical boundaries
dk at look k, k = 1, ..., K, can be found in Chapter 3. If Sk < dk, k = 1, ..., K−1,
the trial proceeds with all of the treatments to the next interim analysis. If the
trial reaches the end of the study and SK < dK , we accept HG0 and claim that
there is no difference between the experimental treatments and the control. If
Sk ≥ dk, k = 1, ..., K, we reject HG0 and start pairwise comparisons.
For all pairwise comparisons, three pairwise tests are conducted at each look.
For comparisons with a control, there are two pairwise tests. Here, compar-
isons with a control are considered. We wish to test the pairwise null hypotheses
H
(j)
0 : µEj = µC versus H
(j)
a : µEj 6= µC for j = 1, 2. These pairwise null
hypotheses are tested repeatedly at each interim analysis. The two-sample test
statistics Zk and the sequential critical boundaries ck shown in Chapter 2 can
be used. These critical boundaries do not take into account the number of pair-
wise tests conducted, as for Fisher’s LSD method in a fixed-sample design. Two
error probabilities are considered: (I) the probability of rejecting at least one of
the two null hypotheses; and (II) the probability of rejecting both null hypotheses.
Let ZjC,k, j = 1, 2, refer to the test statistic for comparing treatment Ej with
the control C at look k. Suppose that a higher value of the test statistic indicates
that the corresponding experimental treatment has greater efficacy. There are sev-
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eral outcomes of the pairwise tests for J = 3 treatments, which include the control.
a. If Z1C,k ≥ ck and Z2C,k ≥ ck, we stop the trial and claim that both exper-
imental treatments are superior to the control.
b. If Z1C,k ≤ −ck and Z2C,k ≤ −ck, we stop the trial and claim that both ex-
perimental treatments are inferior to the control.
c. If Z1C,k ≥ ck and Z2C,k ≤ −ck, we stop the trial and claim that E1 is su-
perior and E2 is inferior to the control.
d. If Z1C,k ≤ −ck and Z2C,k ≥ ck, we stop the trial and claim that E1 is in-
ferior and E2 is superior to the control.
e. If Z1C,k ≥ ck and −ck < Z2C,k < ck, we stop the trial and claim that E1
is superior to the control.
f. If −ck < Z1C,k < ck and Z2C,k ≥ ck, we stop the trial and claim that E2
is superior to the control.
g. If Z1C,k ≤ −ck and −ck < Z2C,k < ck, k = 1, ..., K − 1, we drop E1 and
continue with E2 and C to the next look. When k = K, we claim that E1 is
inferior to the control, but that there is no difference between E2 and C.
h. If −ck < Z1C,k < ck and Z2C,k ≤ −ck, k = 1, ..., K − 1, we drop E2 and
continue with E1 and C to the next look. When k = K, we claim that E2 is
inferior to the control, but that there is no difference between E1 and C.
i. If −ck < Z1C,k < ck and −ck < Z2C,k < ck, k = 1, ..., K − 1, we continue
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with all of the treatments and conduct the pairwise tests again at the next look.
When k = K, we claim that there is no difference between the treatments.
For cases a, b, c and d, where both pairwise null hypotheses are rejected, the
trial stops. For cases e, f, g and h, where one of the two null hypotheses is re-
jected, since a superior treatment has been found for cases e and f, the trial stops.
For cases g and h, where an inferior treatment is identified, the design allows
dropping of the inferior arm and proceeds to the next look with more information
to test the difference between the other experimental treatment and the control.
When the global null hypothesis HG0 is rejected, the probability of encountering
case i is small. However, it can occur, since different test statistics and critical
boundaries are used for the global and pairwise tests.
When the number of treatments J increases, there are more possible outcomes.
For comparisons with a control, there are 3J−1 outcomes. For all pairwise com-
parisons, there are 3J(J−1)/2 outcomes.
4.2. Information time
Immediate responses
The formulae for the information time for trials that allow dropping of inferior
treatment(s) are different from those described in previous chapters. Suppose
that N is the planned maximum number of patients. Recall that the information
time for immediate responses is a ratio of the current sample size to the maximum
sample size N . For trials with dropping of inferior treatments, Follmann et al.
(1994) defined the information time as the current number of subjects on the
arms remaining in the trial divided by the total number of patients planned for
these arms, that is,
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∈ (0, 1], k = 1, ..., K,
where C represents the current set of treatments remaining in the study, which is
a subset of {1, ..., J}, mj,k is the cumulative number of patients on treatment j at













where nk is the cumulative sample size at look k. This shows that the information
time at look k remains the same if some treatments are dropped at this look. The
information time increases when the trial proceeds, with t0 = 0 and tK = 1.
For optimal response-adaptive randomisation, the total sample size on treatment
j, Mj, is random. However, Mj can be approximated by ρjN , since Mj/N con-
verges almost surely to the pre-specified desired optimal allocation proportion






∈ (0, 1], k = 1, ..., K, (4.1)
where ρ̂j is the current estimate of ρj, since the optimal allocation proportions
usually depend on the unknown parameters. Then the optimal allocation pro-
portions (ρ1, ..., ρJ) for multi-armed clinical trials described in Section 3.2.1 can
be used. More specifically, the optimal allocation proportions without treatment
dropping are used in (4.1), so that ρ̂jN is an estimate of the original planned total
sample size on treatment j, Mj. Note that
∑
j∈C ρ̂j ≤ 1, since
∑J
j=1 ρ̂j = 1.
Applying (4.1) with the error-spending approach, the number of interim tests,
K, is not required to be pre-specified, and interim analysis can be planned at any
continuous information time tk ∈ [0, 1) . In addition, one can calculate the total
expected number of patients needed at look k when some inferior treatment(s)
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where dxe is the smallest integer greater than or equal to x.
For equal allocation, ρ̂j = 1/J, j = 1, ...., J . Let m.k be the cumulative sam-
ple size for each treatment at look k and et r be the number of arms remaining in














∈ (0, 1], k = 1, ..., K.
So the number of patients needed for each treatment at look k is m.k = dtkN/Je.
Censored survival responses
Recall that, for censored survival responses, the information time is proportional
to the number of events. For censored survival trials with treatment dropping,
the information time can be approximated by the ratio of the expected number
of events on the remaining arms at look k to the expected total number of events











where êk is the estimated number of events at look k, ê
(k)
K is the estimated num-
ber of events at the end of the trial evaluated based on the responses obtained
so far and ε̂j,k is the estimated probability of an event on arm j at look k. As
mentioned in Sections 2.3.1 and 3.1.1, there are two candidates for the probability
of an event. One is under the null hypothesis where the parameters are all equal
and the other is under a specified alternative. However, both can be used with the
error-spending function to control the overall type I error rate (Kim et al., 1995).
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For simplicity, we consider the information time scale under HG0 , where θ1 = ... =
θJ , and hence ε̂j,k and ε̂j,K can be replaced by ε̂k and ε̂K , respectively. In addition,
for optimal response-adaptive randomisation, Mj can be approximated by ρ̂jN .









∈ (0, 1], k = 1, ..., K. (4.2)
Since the probability of an event at look k, εk, and the optimal allocation propor-
tion for arm j, ρj, depend on the unknown parameters, the parameter estimates
are used here. The accuracy of the parameter estimates increases in the later
stages of the trial with a larger cumulative sample size. The use of the O’Brien
and Fleming critical boundaries, which allocate little type I error rate to the early
group sequential tests, seems to be more sensible.
4.3. Optimal response-adaptive randomisation
Permuted-block randomisation is used for the first 10% of the maximum number
of patients, N , to obtain initial parameter estimates. Then the optimal allocation
proportions (ρ1, ..., ρJ) for multi-armed clinical trials, the DA-optimal allocation
and the optimal allocation based on nonlinear programming (NP), described in
Section 3.2.1, can be used when no treatment has been dropped. However, if the
number of arms remaining in the study decreases as one or more inferior treat-
ments are dropped, the allocation proportions for the remaining arms will increase
(Follmann et al., 1994).
The new optimal allocation proportion for treatment j, ρ
′
j, after some arm(s)
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j = 1, (4.3)
where C is the current set of arms, Mj is the total sample size for treatment j,
which can be approximated by ρ̂jN for optimal response-adaptive designs, and ρ̂j
is the estimated optimal allocation proportion for treatment j without dropping
of inferior treatment(s) based on the responses available.
The optimal response-adaptive randomisation procedures DBCD and ERADE for
multi-armed trials described in Section 3.2.2 can be applied to target the optimal
allocation proportion ρj or ρ
′
j if some treatments have been dropped.
4.4. Simulation studies
4.4.1. Three-armed normal trials
Consider comparing J = 3 treatments using the analogue of Fisher’s LSD method.
Let E1 and E2 denote the experimental treatments and C refers to the control.
First, for the test of homogeneity, the global null hypothesis HG0 : µG = 0 versus
the alternative hypothesis HGa : µG 6= 0, where µG = (µE1 − µC , µE2 − µC)T ,
is considered. The nominal type I error rate α = 0.05 was set. The O’Brien and
Fleming boundaries (18.36, 9.18, 6.12) for three equally spaced group sequential
analyses were used. The critical values for the chi-squared statistics are obtained
from Table 16.1 in Jennison and Turnbull (2000).
If HG0 is rejected, then the pairwise null hypotheses H
(j)
0 : µEj = µC versus
the alternative hypotheses H
(j)
a : µEj 6= µC , j = 1, 2, are tested subsequently.
The O’Brien and Fleming boundaries (3.731, 2.504, 1.994) were used for each
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pairwise Z test. These critical values were computed for the equally spaced in-
formation times (0.33, 0.67, 1) using a program provided by Proschan et al. (2006).
The two group-sequential response-adaptive designs DBCD and ERADE are com-
pared with the group-sequential non-adaptive design CR in terms of the error
probabilities (I: the probability of rejecting at least one of the pairwise null hy-
potheses and II: the probability of rejecting all pairwise null hypotheses), the
expected number of patients (ENP) and the average allocation proportions with
standard deviations. For the optimal response-adaptive designs, permuted-block
randomisation is used for the first 10% of the N patients to obtain initial param-
eter estimates. Then the DBCD and ERADE functions with tuning parameters
γ = γ
′
= 2 are used to compute the allocation probability for the next patient.
For normal responses, the DA-optimal allocation is used as the desired allocation.
The results are based on 5,000 replicates.
Treatment(s) inferior to the control are allowed to be dropped after the pairwise
tests. Taking different reference groups may influence the decisions of treatment
dropping and/or trial termination. More precisely, when µE1 > µE2 > µC or
µE2 > µE1 > µC , the test are unlikely to identify and drop an experimental treat-
ment inferior to the control. However, they may result in early stopping of the
trial with the claim that one or more experimental treatments are superior to the
control. If both experimental treatments are found to be significantly inferior to
the control (µC > µE1 > µE2 or µC > µE2 > µE1), the trial stops. If one ex-
perimental treatment has shown significant inefficacy but the other one has not
yet shown any difference in efficacy compared to the control (µE1 > µC > µE2 or
µE2 > µC > µE1), we drop the inferior arm and continue the others to the next
look. The order of E1 and E2 does not affect the results. In this section, one of
each case is investigated.
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As shown in Table 4.1, the simulated type I error rate α̃I is close to 0.05 for all of
the designs. Generally, α̃I is within one standard error of 0.05. Under HG0 , the
chance of rejecting both null hypotheses, α̃II , is very small. Most trials continued
to the end of the study without early termination and dropping of inferior arms.
The ENP is about the same as the maximum number of patients, N . In addition,
for the DBCD and the ERADE, the DA-optimal allocation without dropping of
arms is (0.454, 0.356, 0.191), which assigns more patients to the treatment with a
larger variance in the responses. The desired DA-optimal allocation proportions
are well targeted. Also, in this case, the standard deviations of the allocation
proportions are lower for the response-adaptive designs than for CR.
Table 4.1.: Simulated type I error rates for three-armed normal trials using com-
plete randomisation and response-adaptive randomisation with drop-
ping of inferior treatment, µE1 = µE2 = µC = 1, σE1 = 4, σE2 =
2, σC = 1, N = 300.
Procedure α̃I α̃II ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃c (s.d.)
CR 0.046 0.002 299.3 (8.0) 0.334 (0.026) 0.333 (0.026) 0.334 (0.026)
DBCDDA 0.048 0.002 299.3 (7.3) 0.453 (0.016) 0.355 (0.019) 0.192 (0.019)
ERADEDA 0.047 0.004 299.4 (6.7) 0.451 (0.013) 0.355 (0.016) 0.194 (0.017)
Table 4.2.: Simulated powers for three-armed normal trials using complete ran-
domisation and response-adaptive randomisation with dropping of in-
ferior treatment, µE1 = 2, µE2 = 1.5, µC = 1, σE1 = 4, σE2 = 2, σC =
1, N = 300.
Procedure powerI powerII ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃c (s.d.)
CR 0.777 0.230 264.2 (49.1) 0.333 (0.027) 0.334 (0.028) 0.334 (0.028)
DBCDDA 0.808 0.276 260.2 (51.5) 0.453 (0.016) 0.355 (0.020) 0.192 (0.020)
ERADEDA 0.815 0.273 259.3 (51.0) 0.451 (0.013) 0.355 (0.017) 0.194 (0.019)
Table 4.2 considers the case where the control is inferior to the two experimental
therapies. In this case, the ENP is about 264 for group sequential CR design and
260 for the the group-sequential response-adaptive designs, since the trials are
allowed to stop early for superiority at interim analyses. Compared to CR, the
response-adaptive designs can increase the power while using fewer patients. For
example, the ERADE increases the power by nearly 4% while using five fewer pa-
tients on average compared to CR. Again, the target DA-optimal allocation with-
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out dropping inferior treatments is (0.454, 0.356, 0.191). Both adaptive designs
target the DA-optimal allocation proportion well, with the ERADE consistently
having lower standard deviations for the allocation proportions.
Table 4.3.: Simulated powers for three-armed normal trials using complete ran-
domisation and response-adaptive randomisation with dropping of in-
ferior treatment, µE1 = 1, µE2 = 2, µC = 1.5, σE1 = 4, σE2 = 2, σC =
1, N = 300.
Procedure powerI powerII ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃c (s.d.)
CR 0.614 0.086 280.0 (39.2) 0.331 (0.028) 0.335 (0.027) 0.334 (0.027)
DBCDDA 0.653 0.092 279.8 (39.0) 0.446 (0.028) 0.358 (0.024) 0.197 (0.020)
ERADEDA 0.652 0.086 280.6 (38.5) 0.445 (0.025) 0.357 (0.022) 0.198 (0.019)
Table 4.3 considers the case where one experimental treatment is superior and
one is inferior to the control. In this case, trials may stop early with the claim
that a treatment is superior or drop the inferior treatment at an interim anal-
ysis. Here, the ENP is about 280 for the group sequential designs. Compared
to the previous table, powerI reduces to about 61% for CR and 65% for the
response-adaptive designs, since the contrasts of the means between the experi-
mental treatments and the control are smaller in this case. For the DBCD and the
ERADE, the target DA-optimal allocation is (0.454, 0.356, 0.191) if no treatment







E2 = ρE2/(ρE2 + ρC) = 0.356/(0.356 + 0.191) = 0.651 and ρ
′
C = 1− ρ
′
E2 = 0.349.
Hence, the average allocation proportion for E1, ρ̃E1, is a little lower than 0.454.
However, since the contrast between E1 and the control is small, the chance of
dropping E1 may not be very high. Therefore, the difference between ρ̃E1 and ρE1
is small.
Table 4.4 considers the case where both experimental therapies are inferior to the
control. The target DA-optimal allocation is (0.454, 0.356, 0.191) if no inferior
treatment is dropped. If arm E1 is dropped, the target DA-optimal allocation
becomes (0, 0.651, 0.349). If arm E2 is dropped, it becomes (0.704, 0, 0.296).
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Compared to the previous tables, the standard deviations for the allocation pro-
portions increase for all of the designs, especially the adaptive ones, since the
chance of dropping arm(s) is increased in this case. With smaller standard devi-
ations σE2 and σC , the difference between E2 and the control can be statistically
significant. However, the response-adaptive designs achieve a slightly lower power
than the CR. This may be due to the slightly greater variability in the allocation
proportions for the DBCD and the ERADE compared to CR. Nevertheless, powerI
is still quite high for all of the designs.
Table 4.4.: Simulated powers for three-armed normal trials using complete ran-
domisation and response-adaptive randomisation with dropping of in-
ferior treatment, µE1 = 1.5, µE2 = 1, µC = 2, σE1 = 4, σE2 = 2, σC =
1, N = 300.
Procedure powerI powerII ENP (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃c (s.d.)
CR 0.983 0.221 264.9 (26.7) 0.363 (0.034) 0.273 (0.049) 0.364 (0.035)
DBCDDA 0.976 0.250 270.1 (26.3) 0.490 (0.039) 0.292 (0.053) 0.218 (0.025)
ERADEDA 0.969 0.253 270.5 (26.1) 0.488 (0.038) 0.293 (0.053) 0.219 (0.025)
4.4.2. Three-armed binary trials
Consider testing the contrasts of the probabilities of success between two exper-
imental treatments and a control. First, we wish to test the global null hy-
pothesis HG0 : pG = 0 versus the alternative hypothesis HGa : pG 6= 0, where
pG = (pE1 − pC , pE2 − pC)T . If HG0 is rejected, then pairwise comparisons
with the null hypotheses H
(j)
0 : pEj = pC versus the alternative hypotheses
H
(j)
a : pEj 6= pC , j = 1, 2, are tested subsequently. For the response-adaptive
designs, the DA-optimal allocation and the optimal allocation based on nonlinear
programming (NP) are used and compared. For the NP allocation, the lower
bound for the allocation proportions B is set to be 0.25. This is chosen as
B ∈ [0, B̃], B̃ = min(B̃1, B̃3, 1/3), where B̃1 and B̃3 are obtained from (3.11).
The other simulation settings are the same as in Section 4.4.1.
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Under HG0 , from Table 4.5, there is a conservative type I error rate α̃
I for all
of the designs. This may be because small treatment contrasts with large vari-
ances are obtained when pE1 = pE2 = pC = 0.5. Under HG0 , the probabilities of
early termination and dropping arms are small. The ENP is about 600 and the
ENF is about 300. In addition, the average allocation proportions are close to
equal allocation for all of the designs. The use of the DA-optimal allocation yields
the smallest standard deviations for the allocation proportions, whereas the use of
the NP allocation gives the largest variability, since this assigns patients according
to the order of the parameter estimates, which is random under HG0 .
Table 4.5.: Simulated type I error rates for three-armed binary trials using com-
plete randomisation and response-adaptive randomisation with drop-
ping of inferior treatment, pE1 = pE2 = pC = 0.5, N = 600.
Procedure α̃I α̃II ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.040 0.008 599.0 (12.4) 299.7 (13.6) 0.333 (0.019) 0.333 (0.019) 0.333 (0.018)
DBCDDA 0.040 0.008 598.8 (14.3) 299.6 (14.0) 0.333 (0.010) 0.333 (0.010) 0.333 (0.009)
ERADEDA 0.042 0.007 598.8 (15.1) 299.7 (14.3) 0.333 (0.007) 0.333 (0.007) 0.333 (0.006)
DBCDNP 0.039 0.006 598.8 (14.1) 299.5 (14.2) 0.330 (0.092) 0.335 (0.094) 0.335 (0.094)
ERADENP 0.036 0.006 599.3 (10.5) 299.9 (13.2) 0.332 (0.095) 0.333 (0.095) 0.334 (0.095)
Table 4.6.: Simulated powers for three-armed binary trials using complete ran-
domisation and response-adaptive randomisation with dropping of in-
ferior treatment, pE1 = 0.65, pE2 = 0.55, pC = 0.5, N = 600.
Procedure powerI powerII ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.792 0.103 522.7 (103.2) 226.2 (45.9) 0.333 (0.020) 0.333 (0.019) 0.333 (0.019)
DBCDDA 0.786 0.102 521.9 (103.6) 226.3 (46.1) 0.326 (0.011) 0.336 (0.010) 0.337 (0.010)
ERADEDA 0.794 0.098 522.8 (101.9) 226.7 (45.4) 0.326 (0.008) 0.336 (0.007) 0.337 (0.007)
DBCDNP 0.801 0.063 518.4 (103.0) 216.1 (44.2) 0.463 (0.038) 0.266 (0.037) 0.270 (0.018)
ERADENP 0.791 0.071 521.4 (102.5) 217.2 (43.7) 0.463 (0.036) 0.267 (0.037) 0.270 (0.017)
Table 4.6 considers the case where the control is inferior to the two experimental
treatments. For the response-adaptive designs targeting the DA-optimal alloca-
tion, the target allocation is (0.327, 0.336, 0.337), which is close to equal allocation,
since the difference in the variances of the responses is small among the treatment
arms in this case. As a result, the simulation results for the response-adaptive
designs targeting the DA-optimal allocation are similar to CR. For the response-
adaptive designs targeting the NP allocation, the target allocation is (0.479, 0.25,
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0.271). These designs require slightly fewer patients on average and reduce the
number of failures by about 10 compared to other designs.
Table 4.7 considers the case where one experimental treatment is superior and one
is inferior to the control group. For the DBCD and the ERADE targeting the DA-
optimal allocation, a higher power is achieved with a lower ENP compared to other
designs, whereas, for the response-adaptive designs targeting the NP allocation,
a lower ENF is obtained, since, in this case, the average allocation proportion for
E1, ρ̃E1, is 0.466. Without dropping treatments, the target DA-optimal allocation
is (0.327, 0.337, 0.336) and the target NP allocation is (0.479, 0.271, 0.25). If
E2 is dropped, the target allocation becomes (0.493, 0, 0.507) for the DA-optimal
allocation and (0.657, 0, 0.343) for the NP allocation.
Table 4.7.: Simulated powers for three-armed binary trials using complete ran-
domisation and response-adaptive randomisation with dropping of in-
ferior treatment, pE1 = 0.65, pE2 = 0.5, pC = 0.55, N = 600.
Procedure powerI powerII ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.641 0.029 560.1 (79.6) 242.3 (36.5) 0.335 (0.021) 0.330 (0.026) 0.335 (0.021)
DBCDDA 0.648 0.028 558.3 (80.9) 242.2 (36.9) 0.328 (0.014) 0.334 (0.020) 0.338 (0.013)
ERADEDA 0.654 0.033 556.9 (83.0) 241.7 (37.7) 0.328 (0.012) 0.333 (0.020) 0.338 (0.011)
DBCDNP 0.626 0.017 560.3 (79.8) 233.3 (35.3) 0.466 (0.035) 0.267 (0.019) 0.266 (0.036)
ERADENP 0.625 0.015 562.4 (77.7) 234.4 (34.6) 0.466 (0.035) 0.267 (0.019) 0.267 (0.037)
Table 4.8 considers the case where the experimental treatments are inferior to the
control. In this case, a slightly higher powerI yet lower powerII are obtained for
the response-adaptive designs using NP allocation compared to the other designs.
In addition, these designs yield around eight fewer failures. Since more patients are
assigned to the best treatment, which is the control group in this case, ρ̃C=0.478.
Without dropping treatments, the target allocations for the DA-optimal and the
NP allocations are (0.336, 0.337, 0.327) and (0.25, 0.271, 0.479), respectively. If
E1 is dropped, the target allocations become (0, 0.508, 0.492) for the DA-optimal
allocation and (0, 0.361, 0.639) for the NP allocation. If E2 is dropped, the target
allocations are (0.507, 0, 0.493) for the DA-optimal allocation and (0.343, 0, 0.657)
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for the NP allocation. In addition, the difference in the simulation results between
the DBCD and the ERADE is small.
Table 4.8.: Simulated powers for three-armed binary trials using complete ran-
domisation and response-adaptive randomisation with dropping of in-
ferior treatment, pE1 = 0.55, pE2 = 0.5, pC = 0.65, N = 600.
Procedure powerI powerII ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.795 0.490 551.9 (73.7) 238.0 (34.2) 0.341 (0.029) 0.315 (0.042) 0.344 (0.027)
DBCDDA 0.797 0.493 551.0 (75.1) 238.2 (34.6) 0.344 (0.026) 0.320 (0.039) 0.336 (0.021)
ERADEDA 0.791 0.496 549.8 (76.2) 237.6 (35.2) 0.344 (0.025) 0.320 (0.038) 0.336 (0.020)
DBCDNP 0.810 0.474 555.5 (70.0) 230.4 (31.8) 0.270 (0.038) 0.252 (0.032) 0.478 (0.043)
ERADENP 0.819 0.472 555.9 (69.0) 230.4 (31.3) 0.270 (0.039) 0.252 (0.031) 0.478 (0.042)
4.4.3. Three-armed censored survival trials
Consider testing the contrasts of the mean survival times between two exper-
imental treatments and the control. We wish to test the global null hypoth-
esis HG0 : θG = 0 versus the alternative hypothesis HGa : θG 6= 0, where
θG = (θE1 − θC , θE2 − θC)T . If HG0 is rejected, then the pairwise null hypotheses
H
(j)
0 : θEj = θC versus the alternative hypotheses H
(j)
a : θEj 6= θC , j = 1, 2, are
tested. For NP allocation, the lower bound for the allocation proportions B is set
to be 0.2. The value is chosen such that B ∈ [0, B̃], B̃ = min(B̃1, B̃3, 1/3), where
B̃1 and B̃3 are obtained from (3.12), which depend on the probability of having
a non-censored event. The nominal type I error rate, the approximate critical
boundaries and the other simulation settings are the same as in Section 4.4.1.
Under the null hypothesis, from Table 4.9, the simulated type I error rate α̃I is
close to the nominal value for the response-adaptive designs, with less than one
standard error deviation from 0.05 for the DBCD and the ERADE targeting the
DA-optimal allocation, and within three standard errors for the designs targeting
the NP allocation. However, a conservative α̃I is obtained for CR. Under HG0 ,
the ENP and the ENF are similar for all of the designs. In addition, the average
allocation proportions for all of the designs are close to equal allocation, with
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the response-adaptive designs targeting the NP allocation having larger standard
deviations for the allocation proportions compared to other designs.
Table 4.9.: Simulated type I error rates for three-armed censored survival trials us-
ing complete randomisation and response-adaptive randomisation with
dropping of inferior treatment, θE1 = θE2 = θC = 24, N = 312.
Procedure α̃I α̃II ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.033 0.005 311.7 (4.2) 203.5 (8.6) 0.333 (0.026) 0.333 (0.025) 0.333 (0.025)
DBCDDA 0.050 0.006 311.4 (6.3) 203.2 (9.4) 0.334 (0.034) 0.334 (0.034) 0.333 (0.034)
ERADEDA 0.050 0.008 311.3 (7.1) 203.2 (9.8) 0.334 (0.032) 0.333 (0.032) 0.333 (0.031)
DBCDNP 0.042 0.007 311.3 (7.1) 203.2 (9.6) 0.333 (0.091) 0.334 (0.091) 0.333 (0.092)
ERADENP 0.044 0.005 311.5 (6.1) 203.2 (9.2) 0.332 (0.088) 0.334 (0.089) 0.334 (0.090)
Under the alternative hypothesis, in Table 4.10, the target DA-optimal allocation
without dropping treatments is (0.406, 0.323, 0.271) and the optimal allocation
based on nonlinear programming is (0.544, 0.2, 0.256). In this case, the NP
allocation assigns more patients to the best treatment and fewer to the worst
treatment compared to the DA-optimal allocation. The DBCD and the ERADE
targeting the NP allocation yield about eight fewer failures compared with the
response-adaptive designs targeting the DA-optimal allocation. In addition, the
NP designs increase the power by around 3% and require about six fewer patients
on average than the response-adaptive designs with DA-optimal allocation.
Table 4.10.: Simulated powers for three-armed censored survival trials using com-
plete randomisation and response-adaptive randomisation with drop-
ping of inferior treatment, θE1 = 34, θE2 = 24, θC = 20, N = 312.
Procedure powerI powerII ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.716 0.094 295.7 (32.2) 186.5 (25.4) 0.333 (0.026) 0.333 (0.026) 0.333 (0.026)
DBCDDA 0.773 0.112 286.0 (37.8) 176.3 (29.9) 0.408 (0.029) 0.325 (0.038) 0.267 (0.040)
ERADEDA 0.779 0.107 285.5 (37.8) 175.9 (29.6) 0.407 (0.026) 0.325 (0.034) 0.269 (0.036)
DBCDNP 0.799 0.046 280.2 (40.1) 168.3 (32.2) 0.530 (0.092) 0.230 (0.062) 0.240 (0.051)
ERADENP 0.802 0.050 279.3 (40.3) 167.7 (32.3) 0.526 (0.091) 0.233 (0.064) 0.240 (0.049)
For Table 4.11, where one experimental treatment is superior and one is inferior to
the control, the target DA-optimal allocation is (0.271, 0.406, 0.323) and the NP
allocation is (0.256, 0.544, 0.2) without dropping treatments. If E1 is dropped, the
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new target allocation becomes (0, 0.557, 0.443) for the DA-optimal allocation and
(0, 0.731, 0.269) for the NP allocation. The DBCD and the ERADE targeting
the NP allocation consistently have higher standard deviations for the average
allocation proportions compared to other designs. However, the designs using the
NP sampling rule achieve around seven fewer failures compared to the designs
using the DA-optimal allocation and about fifteen fewer failures compared to CR,
since more patients are assigned to the best treatment, E2 in this case. In addition,
the designs targeting the NP allocation reduce the ENP by about four compared
to the designs using the DA-optimal allocation. Although the power of the tests
is also reduced, this may be due to the simulated type I error rates being smaller
for the designs targeting the NP allocation than those targeting the DA-optimal
allocation.
Table 4.11.: Simulated powers for three-armed censored survival trials using com-
plete randomisation and response-adaptive randomisation with drop-
ping of inferior treatment, θE1 = 20, θE2 = 34, θC = 24, N = 312.
Procedure powerI powerII ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.538 0.021 306.6 (18.3) 197.2 (15.9) 0.331 (0.027) 0.334 (0.026) 0.334 (0.026)
DBCDDA 0.615 0.039 300.3 (26.2) 189.4 (21.8) 0.268 (0.043) 0.409 (0.029) 0.324 (0.038)
ERADEDA 0.620 0.040 300.5 (25.9) 189.7 (21.3) 0.269 (0.042) 0.407 (0.027) 0.324 (0.036)
DBCDNP 0.593 0.011 296.3 (30.0) 182.7 (25.3) 0.241 (0.050) 0.529 (0.090) 0.230 (0.061)
ERADENP 0.589 0.015 296.2 (30.0) 182.7 (25.3) 0.243 (0.049) 0.524 (0.088) 0.232 (0.062)
Table 4.12.: Simulated powers for three-armed censored survival trials using com-
plete randomisation and response-adaptive randomisation with drop-
ping of inferior treatment, θE1 = 20, θE2 = 24, θC = 34, N = 312.
Procedure powerI powerII ENP (s.d.) ENF (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃C (s.d.)
CR 0.705 0.382 304.2 (18.8) 194.1 (15.3) 0.324 (0.034) 0.338 (0.028) 0.338 (0.028)
DBCDDA 0.763 0.466 299.1 (25.1) 187.1 (20.5) 0.259 (0.052) 0.328 (0.042) 0.413 (0.034)
ERADEDA 0.768 0.465 299.6 (24.7) 187.4 (20.3) 0.261 (0.050) 0.328 (0.040) 0.411 (0.031)
DBCDNP 0.809 0.480 293.4 (28.7) 179.8 (23.9) 0.229 (0.054) 0.230 (0.060) 0.540 (0.093)
ERADENP 0.807 0.480 293.0 (29.2) 179.4 (24.4) 0.231 (0.053) 0.234 (0.061) 0.535 (0.093)
For Table 4.12, where the experimental treatments are inferior to the control, the
target DA-optimal allocation is (0.271, 0.323, 0.406) and the NP optimal alloca-
tion is (0.256, 0.2, 0.544). If E1 is dropped, the new target allocation becomes (0,
0.443, 0.557) for the DA-optimal allocation and (0, 0.269, 0.731) for the NP allo-
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cation. If E2 is dropped, the new target allocation becomes (0.400, 0, 0.600) for
the DA-optimal allocation and (0.320, 0, 0.680) for the NP allocation. Compared
to CR, the average allocation proportions for the DBCD and the ERADE assign
more patients to the best treatment (C) and fewer to the least efficacious treat-
ment (E1), and hence the ENF is reduced. More specifically, about fifteen fewer
failures are achieved for the response-adaptive designs targeting the NP allocation
and about seven fewer failures for the designs using the DA-optimal allocation.
Among the response-adaptive designs, the DBCD and the ERADE targeting the
NP allocation attain a higher power while using about six fewer patients on aver-
age than those using the DA-optimal allocation.
4.4.4. Redesigning a four-armed binary trial
The NeoSphere trial (Gianni et al., 2012) is redesigned using the adaptive designs
with dropping of inferior treatments during the course of the trial. The proba-
bility of success for each treatment is pC = 0.29, pE1 = 0.458, pE2 = 0.168 and
pE3 = 0.24. First, a chi-squared test statistic is monitored for tests of homogene-
ity. The global null hypothesis is HG0 : pG = 0 versus the alternative hypothesis
HGa : pG 6= 0 with pG = (pE1 − pC , pE2 − pC , pE3 − pC)T . Three group sequen-
tial analyses are planned at equally spaced information times. The nominal type
I error rate 0.05 was set. The O’Brien and Fleming critical boundaries derived
based on normal responses with equal variances are used as an approximation.
For the chi-squared statistics, the sequence of critical boundaries at information
times (t1, t2, t3) = (0.33, 0.67, 1) is (23.76, 11.88, 7.92).
If the global null hypothesis is rejected, then J − 1 = 4 − 1 = 3 pairwise Z
tests are carried out at the current and subsequent looks. The null hypotheses
H
(j)
0 : pEj = pC versus the alternative hypotheses H
(j)
a : pEj 6= pC , j = 1, 2, 3, are
tested. Let ZjC,k refer to the pairwise test statistic for comparing treatment Ej
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with the control C at look k. The sequence of critical boundaries for each pairwise
test is (3.731, 2.504, 1.994). The following two error probabilities are considered:
the probability of rejecting at least one of the three null hypotheses, that is, α̃I
under the null hypotheses and powerI under the alternative hypotheses; and the
probability of rejecting all three null hypotheses, that is, α̃II under the null hy-
potheses and powerII under the alternative hypotheses.
Suppose that a higher value of the test statistic indicates that the correspond-
ing experimental treatment has greater efficacy. For the adaptive designs, early
termination is allowed for treatment efficacy or futility. More specifically, trials
stop when one or more of the treatments have been found superior to the con-
trol or when all of the experimental treatments are inferior to the control. Trials
proceed when more information is needed on all of the treatments or when some
treatment(s) have been found inferior to the control while others have not been
shown to be significantly different from the control. The possible cases when trials
continue to the next look are shown below.
(i). If Z1C,k ≤ −ck, |Z2C,k| < ck and |Z3C,k| < ck, k = 1, ..., K − 1, then E1
is dropped and E2, E3 and the control are continued to the next look.
(ii). If |Z1C,k| < ck, Z2C,k ≤ −ck and |Z3C,k| < ck, k = 1, ..., K − 1, then E2
is dropped and E1, E3 and the control are continued to the next look.
(iii). If |Z1C,k| < ck, |Z2C,k| < ck and Z3C,k ≤ −ck, k = 1, ..., K − 1, then E3
is dropped and E1, E2 and the control are continued to the next look.
(iv). If Z1C,k ≤ −ck, Z2C,k ≤ −ck and |Z3C,k| < ck, k = 1, ..., K − 1, then
E1 and E2 are dropped. E3 and the control are continued to the next look.
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(v). If Z1C,k ≤ −ck, |Z2C,k| < ck and Z3C,k ≤ −ck, k = 1, ..., K − 1, then E1
and E3 are dropped. E2 and the control are continued to the next look.
(vi). If |Z1C,k| < ck, Z2C,k ≤ −ck and Z3C,k ≤ −ck, k = 1, ..., K − 1, then
E2 and E3 are dropped. E1 and the control are continued to the next look.
(vii). If |Z1C,k| < ck, |Z2C,k| < ck and |Z3C,k| < ck, k = 1, ..., K − 1, then all
treatments are continued to the next look.
In addition, fixed-sample designs are provided alongside for comparison. For these,
the critical boundary for the chi-squared test is 7.81. The critical value for all three
pairwise test statistics is 1.96. For optimal response-adaptive randomisation, the
DA-optimal allocation and the optimal allocation based on nonlinear programming
(NP) described in Section 3.2.1 can be used if no arm has been dropped. For the
NP optimal allocation, the lower bound for the allocation proportions B is set to
be 0.2. After dropping treatments, (4.3) is used to obtain the optimal allocation
proportions for the remaining arms.
As can be seen in Table 4.13, under the null hypothesis, the type I error rate α̃I is
within three standard errors of 0.05 for both the group sequential and the fixed-
sample designs. The adaptive designs that combine group sequential analysis with
optimal response-adaptive randomisation procedures, which allow dropping of in-
ferior treatments during the course of the trial, can well preserve the overall type
I error rate. Under the null hypotheses, the DA-optimal allocation becomes equal
allocation. For the NP allocation, patients are sequentially assigned according to
the order of the current parameter estimates. The variability in the allocation
proportions is much higher than for the other designs.
Under the alternative hypothesis, in Table 4.14, a similar power is obtained for
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Table 4.13.: Simulated type I error rates for redesigning NeoSphere trial using
complete randomisation and response-adaptive randomisation with
dropping of inferior treatment(s), pC = 0.29, pE1 = 0.29, pE2 =
0.29, pE3 = 0.29, N = 417.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure α̃I α̃II ENP (s.d.) ENF (s.d.) ρ̃C (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃E3 (s.d.)
CR 0.043 0.003 416.3 (8.8) 295.6 (6.2) 0.250 (0.020) 0.250 (0.020) 0.250 (0.021) 0.250 (0.021)
DBCDDA 0.049 0.003 415.7 (15.6) 295.1 (11.1) 0.250 (0.012) 0.250 (0.013) 0.250 (0.013) 0.250 (0.012)
ERADEDA 0.047 0.004 415.9 (12.9) 295.3 (9.2) 0.250 (0.010) 0.250 (0.010) 0.250 (0.010) 0.250 (0.010)
DBCDNP 0.047 0.002 416.0 (13.1) 295.3 (9.3) 0.241 (0.108) 0.247 (0.117) 0.249 (0.118) 0.263 (0.104)
ERADENP 0.050 0.002 415.9 (13.0) 295.3 (9.3) 0.243 (0.109) 0.246 (0.115) 0.244 (0.116) 0.267 (0.103)
Fixed-sample design
Procedure α̃I α̃II ENP (s.d.) ENF (s.d.) ρ̃C (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃E3 (s.d.)
CR 0.042 0.002 417 (0) 296.1 (0) 0.250 (0.020) 0.250 (0.020) 0.250 (0.020) 0.250 (0.020)
DBCDDA 0.045 0.002 417 (0) 296.1 (0) 0.250 (0.011) 0.250 (0.011) 0.250 (0.011) 0.250 (0.011)
ERADEDA 0.047 0.004 417 (0) 296.1 (0) 0.250 (0.009) 0.250 (0.009) 0.250 (0.009) 0.250 (0.009)
DBCDNP 0.044 0.002 417 (0) 296.1 (0) 0.242 (0.108) 0.245 (0.117) 0.246 (0.116) 0.266 (0.104)
ERADENP 0.044 0.003 417 (0) 296.1 (0) 0.241 (0.107) 0.246 (0.115) 0.245 (0.115) 0.268 (0.105)
Table 4.14.: Simulated powers for redesigning NeoSphere trial using complete ran-
domisation and response-adaptive randomisation with dropping of in-
ferior treatment(s), pC = 0.29, pE1 = 0.458, pE2 = 0.168, pE3 =
0.24, N = 417.
(t1, t2, t3)=(0.33, 0.67, 1)
Procedure powerI powerII ENP (s.d.) ENF (s.d.) ρ̃C (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃E3 (s.d.)
CR 0.944 0.007 364.7 (63.3) 258.5 (45.0) 0.255 (0.024) 0.255 (0.024) 0.238 (0.034) 0.252 (0.026)
DBCDDA 0.944 0.005 360.3 (66.6) 253.4 (47.0) 0.260 (0.020) 0.272 (0.017) 0.218 (0.036) 0.250 (0.022)
ERADEDA 0.948 0.009 361.7 (65.7) 254.5 (46.3) 0.260 (0.019) 0.272 (0.016) 0.219 (0.034) 0.249 (0.022)
DBCDNP 0.942 0.005 356.6 (71.6) 234.4 (47.3) 0.198 (0.035) 0.472 (0.033) 0.143 (0.033) 0.187 (0.033)
ERADENP 0.939 0.005 356.8 (70.8) 234.9 (46.8) 0.198 (0.033) 0.470 (0.032) 0.145 (0.032) 0.187 (0.031)
Fixed-sample design
Procedure powerI powerII ENP (s.d.) ENF (s.d.) ρ̃C (s.d.) ρ̃E1 (s.d.) ρ̃E2 (s.d.) ρ̃E3 (s.d.)
CR 0.946 0 417 (0) 296.5 (2.1) 0.250 (0.020) 0.250 (0.020) 0.250 (0.020) 0.250 (0.020)
DBCDDA 0.953 0 417 (0) 294.3 (1.3) 0.256 (0.012) 0.267 (0.011) 0.230 (0.015) 0.248 (0.012)
ERADEDA 0.948 0 417 (0) 294.3 (1.0) 0.256 (0.009) 0.266 (0.008) 0.230 (0.013) 0.248 (0.010)
DBCDNP 0.947 0 417 (0) 274.4 (2.8) 0.198 (0.030) 0.470 (0.033) 0.145 (0.029) 0.187 (0.030)
ERADENP 0.947 0 417 (0) 274.7 (2.6) 0.198 (0.028) 0.468 (0.030) 0.147 (0.027) 0.188 (0.027)
• The target DA-optimal allocation (ρC , ρE1, ρE2, ρE3) is (0.256, 0.266, 0.230, 0.248) and the
NP optimal allocation is (0.2, 0.479, 0.121, 0.2) if no arm has been dropped.
• If E2 is dropped, the optimal allocation becomes (0.332, 0.345, 0, 0.322) for the DA-optimal
allocation and (0.228, 0.545, 0, 0.228) for the NP allocation.
• If E3 is dropped, the optimal allocation becomes (0.340, 0.354, 0.306, 0) for the DA-optimal
allocation and (0.250, 0.599, 0.151, 0) for the NP allocation.
• If both E2 and E3 are dropped, the optimal allocation becomes (0.490, 0.510, 0, 0) for the
DA-optimal allocation and (0.295, 0.705, 0, 0) for the NP allocation.
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all of the designs. However, use of the group-sequential response-adaptive designs
can reduce the ENP and the ENF compared to the group-sequential CR design.
More specifically, about four fewer patients on average and five fewer failures are
achieved for the adaptive designs with the DA-optimal allocation, and around
eight fewer patients on average and 24 fewer failures can be achieved for those
with the NP allocation.
Both optimal response-adaptive designs, the DBCD and the ERADE, can tar-
get the optimal allocations well. The use of the ERADE with the DA-optimal
allocation consistently attains the lowest standard deviations for the allocation
proportions compared to the other designs. Similar conclusions can be drawn for
the fixed-sample designs. Compared to these, the group sequential designs can
require 52-61 fewer patients on average and prevent around 40 failures while at-
taining similar error probabilities.
4.5. Conclusions
Simulation results show that the group-sequential response-adaptive designs with
dropping of inferior treatments can well control the overall type I error rate. More
precisely, the probability of falsely rejecting one or more pairwise null hypotheses
when the parameters are all equal is less than or equal to 5%. In addition, the
combined approach can achieve a higher or similar power while using fewer pa-
tients compared to the group sequential CR design. Furthermore, fewer failures
are obtained for the adaptive designs. It is concluded that the combined approach
can be more ethical in terms of reducing the total sample size and the total num-
ber of failures in a trial, since early stopping for efficacy and futility and dropping
inferior arms at interim looks are allowed.
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As shown in Section 3.3.4 where the NeoSphere trial is redesigned using the com-
bined approach without dropping treatments, the type I error rate is slightly
inflated. For the tests of homogeneity considered in Chapter 3, the critical bound-
aries under the assumption of equal variances for all treatments are used as an
approximation. However, heterogeneity increases when the treatments have un-
equal variances, which can result in a higher probability of rejecting the global
null hypothesis.
Nevertheless, if the global null hypothesis is rejected, pairwise comparisons are
conducted subsequently using Fisher’s LSD method in Chapter 4. The critical
boundaries for the pairwise Z tests can be applied for different variances and
unequal numbers of patients on the treatment arms, since the sequence of test
statistics still asymptotically has the canonical joint distribution (Jennison and
Turnbull, 2000). Therefore, although a false rejection of the global null hypothesis
could be made using the critical boundaries derived under the assumption of equal
variances, this would just lead to the commencement of pairwise comparisons, and





Group sequential monitoring has become a standard procedure in clinical trials.
In addition, the use of response-adaptive randomisation can be more ethical, since
the probability that a newly-arrived patient will receive the more promising treat-
ment is increased. However, few researches have explored the properties of the
combined approach of group sequential analysis with response-adaptive randomi-
sation. The application of this approach to two-armed and multi-armed clinical
trials with different types of responses is investigated in this thesis. Simulation re-
sults show that the approach can control the overall type I error rate and that the
power is not adversely affected by the adaptive sampling rules. Furthermore, with
the use of an optimal response-adaptive randomisation procedure, the approach
can target any optimal allocation derived based on some optimality criterion. The
ERADE in particular has the smallest variability in the allocation proportions.
The combined approach has the advantage of being ethical in terms of reducing
the expected number of patients and the expected number of failures for binary
and censored survival responses. Moreover, the approach does not require nu-
merical iterative methods to obtain the optimal allocation proportions. Existing
critical boundaries can be used as an approximation to control the overall type I
error rate, which facilitates the use of the combined approach.
The designs allow interim looks to be taken at any continuous information time.
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For two-treatment comparisons, the error-spending approach can be used to obtain
the critical boundaries for unequally spaced information times. These boundaries
can be applied to response-adaptive designs, as long as the imbalance in the al-
location is not too severe. For comparing multiple treatments, an analogue of
Fisher’s LSD method, which consists of a global test and pairwise tests, is consid-
ered. In a fixed-sample design, Fisher’s LSD method has been shown to control
the family-wise type I error rate, although not strongly. However, it is considered
as one of the most powerful multiple comparison approaches (Christensen, 2002).
For the global tests, the critical boundaries derived under the assumptions of
equal allocation and equally spaced information times are used as an approxima-
tion. This may result in a higher probability of rejecting the global null hypothesis
when the assumptions are violated. Nevertheless, simulation results in Chapter
3 show that the inflation in the type I error rate seems to be modest, except for
binary responses with small sample sizes and when the probabilities of success for
all treatments are close to zero or one. When the global null hypothesis is rejected,
pairwise tests are conducted subsequently. The above-mentioned boundaries for
two-treatment comparisons can then be used to control the error probabilities. As
can be seen from the simulation results in Chapter 4, the probability of rejecting
one or more pairwise null hypotheses is generally less than or equal to the specified
significance level.
For optimal allocations, the DA-optimal design was derived based on the general
linear model for multi-armed normal trials with unequal variances across treat-
ments. The optimal rule was generalised to censored survival responses (Sverdlov
et al., 2011). Here, the DA-optimal allocation is also applied to binary responses.
The allocation rule depends on the variances of the responses for each treatment
arm. Computation of the target optimal allocation requires that the estimates
for the variances are reliable. The DA-optimal allocation is ethical for censored
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survival responses. If the mean survival times are θ1 > θ2 ≥ ... ≥ θJ−1 > θJ , then
the DA-optimal allocation proportions satisfy ρ1 > ρ2 ≥ ... ≥ ρJ−1 > ρJ .
The optimal allocation based on nonlinear programming (NP) depends on the
order of the unknown parameters and the user-specified lower bound for the allo-
cation proportions B. The NP allocation assigns more patients to the best and
the worst treatments and fixes the allocation proportions for the other treatments
to be B. The simulation results show that the NP allocation can be more ethical
in terms of reducing the total number of failures for binary and survival responses.
However, the least promising treatment arm usually receives more patients than
the arms with medium efficacy. As discussed in Section 3.2.1, for normal responses
with a nuisance parameter, a closed form solution has not yet been derived and
further research is needed. The closed form solution for binary and censored sur-
vival responses can be used. With a closed form, the simulation results for the
NP allocation usually take less time than for the DA-optimal allocation.
Simulation results on comparing two, three and four treatments are shown. These
are often the cases for phase III trials. Nevertheless, the combined approach is also
applicable for J > 4 arms. Both optimal response-adaptive randomisation proce-
dures, the DBCD and the ERADE, have been generalised to multi-armed clinical
trials. In addition, the DA-optimal allocation and the NP optimal allocation can
be applied. However, when the number of treatments increases, the computation
time for the DA-optimal allocation, which solves a system of equations, will in-
crease. For NP optimal allocation, the variability in the order of the parameter
estimates may be higher when the number of treatments increases. Consequently,
a greater variance for the treatment allocation proportions may be obtained. Also,
the number of possibilities after the pairwise comparisons increases significantly.
For comparisons with a control, there are nine possibilities for three-armed trials
and 27 possibilities for four-armed trials. An increase in the number of treatments
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would make the program for the design more complicated.
5.2. Future work
Throughout the thesis, the parameter of interest considered is the simple differ-
ence, which determines the optimal allocation proportions and the test statistics
used. Application of the combined approach to other parameters of interest, such
as the log odds ratio for binary responses and the log hazard ratio for survival
responses, is also worth investigating. Some optimal allocations based on these
parameters for two-armed trials have been proposed. For two-armed binary trials,
Morgan and Coad (2007) studied group-sequential response-adaptive designs using
the log odds ratio. It is shown that, for the test statistic in this case, the normal
approximation is more accurate. For multi-armed trials, the optimal allocations
were derived based on the vector of simple difference parameters, including the
DA-optimal allocation and the NP allocation. A discussion of multi-treatment
optimal allocations can be found in Biswas et al. (2011). There appear to be no
optimal allocations for multi-armed trials derived based on parameters other than
the simple difference.
This thesis focuses on maximum duration trials rather than maximum informa-
tion ones. For a maximum duration trial with censored survival responses, the
information level at the final look is usually unpredictable. An approximate infor-
mation time is defined in Chapter 2. For a maximum information trial, the trial
stops when the specified information is reached. This ensures attainment of the
specified power. However, trials may reach the specified information well before
the planned end of the study, or, at the end of the trial, the target information level
may not be achieved. This increases the difficulty in utilising the error-spending
approach to control the overall type I error rate. Further research is required to
apply the combined approach to maximum information trials.
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For censored survival responses, the optimal allocation usually depends on the
probability of an event, εj,k. For the combined approach, εj,k derived in Appendix
A is based on the model assumptions of uniform arrival and censoring times, and
exponential survival times. Although the assumptions are strong, it is a natural
starting point to begin generalising the design to a group sequential setting. How-
ever, exponential survival times have a constant hazard, which is unrealistic in
practice. Weibull survival times are considered by Zhang and Rosenberger (2007)
for a fixed-sample response-adaptive design comparing two treatments. For multi-
armed trials, Sverdlov et al. (2011) compared fixed-sample response-adaptive de-
signs under the assumption of censored exponential survival times. An interesting
open problem is to generalise the Weibull case to the group sequential setting.
For example, the calculation of εj,k will be more difficult in the Weibull case, as it
requires integration of the joint distribution of the arrival, survival and censoring
times.
This thesis also focuses on testing. Development of inferential methods, such
as a bias-adjusted maximum likelihood estimate and an approximate confidence
interval following group sequential tests, has been studied (Whitehead, 1986; Mor-
gan, 2003a). Research on estimation following the adaptive designs presented here
may also be of interest.
In this thesis, the randomisation procedures depend on the previous treatment
allocations and responses, but they do not take into account the covariates of the
patients. Covariate-adjusted response-adaptive (CARA) designs have been pro-
posed for fixed-sample designs. Designs that combine group sequential monitoring
with CARA designs would be more complicated, yet may be of interest as well.
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A. Calculation of the probability of
an event
Consider the model assumptions described in Section 2.3.2. The observed sur-
vival time for patient i on treatment j at interim analysis k can be expressed as
Yi,j,k = min(Si,j, Ci, Dtk − Ai), where the survival time Si,j ∼ Exp(θ−1j ), the
censoring time Ci ∼ U(0, D) and the arrival time Ai ∼ U(0, Dtk). Here, θj is the
mean survival time for treatment j, D is the maximum duration of the trial and
tk ∈ (0, 1] is the information time at look k.
The probability of having an event on treatment j at look k is

























































where the first term inside the parentheses refers to the case c < Dtk − a and the
second term represents the case c > Dtk − a. Then, by integrating out c, we have
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B. Derivation of the noncentrality
parameter
First, we utilise the following formula in Atkinson (1982) to obtain the inverse of



























































































































In addition, after multiplying V Tk and C
−1
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